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IDENTIFYING PROTEIN KINASE TBK1 AS A NOVEL INHIBITOR OF 
INTESTINAL TUMORIGENESIS 
Amber Lynn Mathews, M.S. 
Advisory Professor: Shao-Cong Sun, Ph.D. 
Colorectal cancer (CRC) is the third most common cancer diagnosed in women and 
men， causing almost 600,000 annual deaths worldwide. There is a clear need to 
understand how CRC forms and progresses in order to improve the strategies of 
CRC prevention and therapy. A major factor that drives the development of CRC is 
genetic mutations that lead to activation of oncogenes and inactivation of tumor 
suppressor genes in intestinal epithelial cells (IECs). In addition, the initiation and 
progression of CRC involve environmental and immunological factors. In particular, 
chronic inflammatory conditions are known as an important risk factor for CRC. 
Intestinal inflammation can be caused by deregulated signaling events in IECs or 
immune cells; and chronic inflammation is often associated with reduced production 
of immunosuppressive cytokines such as interleukin (IL)-10 and aberrant production 
of inflammatory cytokines. However, the signaling factors involved in the regulation 
of intestinal inflammation and tumorigenesis are still poorly defined. Given the 
complexity of the molecular and cellular components contributing to these 
pathogenic processes, animal models represent an important tool for CRC studies.  
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This dissertation focuses on the study of a serine/threonine kinase, TANK 
Binding Kinase 1 (TBK1). Although TBK1 is best known as a mediator of type I 
interferon induction in antiviral innate immunity, recent evidence suggests the 
involvement of TBK1 in several other biological processes including cancer 
development.  Based on in vitro studies using cancer cell lines, TBK1 has been 
implicated as an oncogenic kinase that mediates survival of KRAS-dependent lung 
and other cancers.  However, the oncogenic role of TBK1 is controversial, since this 
finding has been challenged by a more recent study. Moreover, the in vivo role of 
TBK1 in CRC development, particularly during the early phase of adenoma 
formation, has not been studied. This dissertation project took an in vivo approach 
that involves the generation and characterization of an innovative mouse model in 
which Tbk1 is conditionally ablated in IECs.  The data from my dissertation reveals 
an unexpected finding that TBK1 has a tumor-suppressive function in the intestine. 
IEC-specific Tbk1 ablation promotes adenoma formation in mice carrying a mutation 
in the Apc gene, a tumor-suppressor gene commonly mutated in the early stages of 
colon cancer development.  Interestingly, Tbk1 expression is important for the 
crosstalk of IECs with intraepithelial lymphocytes that maintain the expression of 
immunosuppressive cytokine IL-10. These studies present the first in vivo model 
demonstrating the function of TBK1 during the process of intestinal adenoma 
development and suggest a mechanism of TBK1 action. These data also present a 
novel approach in determining the in vivo function of TBK1 early in the tumorigenic 
process as compared to previous findings based on the xenograft model of late-
  x 
staged cancers.  In addition, because the use of TBK1 inhibitor has been suggested 
for possible treatment in cancers of other tissue types, my findings argue for the 
precaution in the selection of treatment modalities targeting TBK1 in these patients; 
it is possible that long-term use of TBK1 inhibitors may pose an increased risk for 
adenoma growth in the intestine.   
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Chapter 1: Specific Aims of the Dissertation  
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality, 
and almost 150,000 people are diagnosed and approximately 50,000 die from this 
disease every year in the United States alone. The development of this disease 
results from dysregulated signal transduction in intestinal epithelial cells (IECs) that 
allows out-of-control growth and/or survival of dysfunctional cells. Several risk 
factors have been associated with CRC, including somatic and germline gene 
mutations, chronic intestinal inflammation, diet and lifestyle. While there has been 
progress in the field, the worldwide incidence of almost 1.2 million people and 
mortality rate of almost 600,000 suggest that there is indeed much to understand 
concerning the intestinal tumorigenic process in order to improve the strategies of 
CRC prevention and treatment. The molecular mechanisms that regulate the 
process of CRC initiation and progression are still poorly understood. The overall 
objective of my dissertation project has been to contribute to the understanding of 
the mechanisms that control intestinal adenoma development. This dissertation 
project contributes to this goal by specifically identifying TANK binding kinase 1 
(TBK1) as a novel negative regulator of intestinal tumor growth using an innovative 
in vivo model.  
TBK1 is a serine/threonine protein kinase that mediates type I interferon 
induction in antiviral innate immune responses. In addition, recent studies using in 
vitro cell culture and xenograft mouse models implicate TBK1 as an oncogenic 
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kinase that supports the survival and drug resistance of human cancer cell lines, 
including those derived from breast cancer, KRAS-driven lung cancers, melanoma, 
and prostate cancer.  However, a more recent study showed that the viability of 
KRAS-mutant cancer cell lines did not correlate with the knockdown or 
pharmacological inhibition of TBK1 in vitro, thus creating controversy in the field. In 
addition, our understanding of the function of TBK1 in cancer is limited by the sole 
use of cell line studies, which models late stages of disease. Therefore, the role of 
TBK1 in regulating the early stage of tumor development, such as the initiation and 
growth of adenomas was not yet addressed. Secondly, the use of mouse xenograft 
models excludes the contribution of functional T lymphocytes to the understanding of 
disease progression. Third, the use of a limited number of human cancer cell lines 
may create variations in results due to the accumulation of different genetic 
alterations. To overcome these limitations, my dissertation project employed a new 
mouse model harboring TBK1 deficiency specifically in IECs. My hypothesis is that 
TBK1 modulates intestinal tumorigenesis in vivo by regulating IEC survival and 
immune homeostasis.  
In testing this hypothesis, my project sought and accomplished the following 
specific aims. In Specific Aim 1 (discussed in Chapter 3), we examined the role of 
TBK1 in intestinal adenoma development by analyzing the effect of IEC-conditional 
Tbk1 knockout on adenoma formation in Apcmin/+ mice and determined that TBK1 in 
IECs regulates intestinal tumorigenesis in vivo. These findings were consistent with 
a strong correlation between TBK1 and APC mRNA expression in patient samples of 
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colorectal adenocarcinomas profiled in The Cancer Genome Atlas (TCGA).  In 
Specific Aim 2 (also discussed in Chapter 3), we devised a series of immunological 
studies to examine whether TBK1 in IECs regulates intestinal immune homeostasis 
in vivo thus affecting the tumorigenic process.  In this aim, we determined that TBK1 
expression is important for the crosstalk of IECs with intraepithelial lymphocytes 
(IELs) that maintains an immunosuppressive environment during intestinal adenoma 
development.  In addition to these in vivo studies, we carried out in vitro and 
xenograft studies in Specific Aim 3 (discussed in Chapter 4) using TBK1-
knockdown human CRC cell lines.  We determined that TBK1 is dispensable for the 
growth of KRAS-competent xenograph tumor growth in immunocompromised hosts. 
The findings presented herein supporting the in vivo function of TBK1 in intestinal 
tumorigenesis provide a better understanding of the molecular mechanisms 
mediating the disease process.  The significance of these findings is discussed 
within each chapter of the dissertation with a particular focus in Chapter 5 
highlighting further implications.  
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Chapter 2: Literature Review 
Epidemiology  
 Colorectal cancer is one of the leading cancer diagnoses globally.   The 
estimated new diagnoses of CRC is approximately 1.2 million being the second most 
common cancer diagnosis in women and third in men1,2. The rate of incidence is 
highest in Australia, New Zealand, North America and Europe. In fact, as compared 
to developing countries, the rates are as many as five times higher in developed 
countries, although differences in methods of medical diagnostics in these regions 
may have partially contributed to these epidemiological numbers. However, the 
recent trend is a steadily reduced incidence rate in economically developed 
countries as a result of screenings and adenomatous polyp removal.  At the same 
time, a rise in incidence is observed in developing countries, which is attributed to 
environmental risk factors such as diet and lifestyle. The time of diagnosis also 
varies between developed and developing countries where late stage diagnosis is 
more common in developing counties and reflected in mortality rates. There are 
about 600,000 estimated worldwide deaths per year from CRC with highest mortality 
rate observed in Southern Africa, central and eastern Europe and Eastern Asia as of 
2008.1 Because of advancement in screenings, treatments and knowledge of 
disease course, there has been a decline in mortality in western countries.1  
However, the challenge remains as mortality rate for CRC is substantial.   
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It is estimated that nearly 140,000 Americans were diagnosed with CRC while 
50,000 succumbed to the disease in 20143. It is currently the third most common 
cancer diagnosis and cause of death among both women and men, despite a trend 
that has steadily declined since the early 1950s when CRC was the leading cause of 
cancer death4,5. The incidence and mortality rates for CRC is greater in men than in 
women. Reasons for gender differences are unknown but speculated to be related to 
differences in sex hormones, risk factors, and adherence to recommended 
screenings6.  
Those aged 65 years old and older hold the majority of new cases at 60 
percent and CRC deaths at 70 percent6. While an overall decline has been observed 
in CRC incidence and mortality rates over the past few decades5, a closer look at 
age related trends revealed that the decline in new cases is observed for those 50 
years and older whereas a steady increase in CRC incidence amongst younger 
adults particularly those 49 years of age or younger6,7.  It is predicted that this rate 
will continue upward in younger adults below the age of 50 years old, the traditional 
CRC screening age. Patients at higher risk, such as those with ulcerative colitis or 
family history of inherited CRC, are advised to undergo CRC screening prior to age 
50 to allow for earlier diagnosis and treatment.  It is believed that the disparity in 
age-related CRC incidence is associated with dietary risk factors such as the 
pervasiveness of obesity and an inactive lifestyle in the younger population7, 
although further research is necessary to determine specifically the effects of these 
behavioral risk factors in CRC incidence in younger groups. 
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A study performed between 2006 and 2010 revealed a trend demonstrating 
differences amongst races and ethnicities, where African Americans have the 
highest rates of incidence and mortality while Asian and Pacific Islanders have the 
lowest6. There is an association between socioeconomic status and risk of incidence 
and mortality from CRC such that low socioeconomic status has higher risk for CRC.  
It is believed that the impact of disproportionately low social economic position of 
African Americans contributes to this imbalance of new cases and death between 
groups as the poverty rate was almost three times and two and half times higher 
amongst African Americans as compared to Caucasians and Asians, respectively.6  
However, other contributing factors, some of which are still unknown, are 
considered, as rates are still considerably higher in African Americans when 
compared with Caucasians who are within the same socioeconomic group.   For 
example, one recent study suggests that behavioral risk factors may come into play 
such as obesity6. While there has been a decline over the more recent years in CRC 
rates5,6, it is clear that there is a need to better understand the relationship between 
risk factors such as diet and lifestyle in addition to others including somatic and 
germline mutations and chronic intestinal inflammation in the development of CRC. 
Intestinal epithelia and immune homeostasis – the norm  
The intestine is an organ with diverse functions, including food digestion, nutrient 
and water absorption, gas exchange, microbial sensing and immunological 
regulation.  Pivotal to the functions of intestine is the epithelium, the largest mucosal 
surface of the body that serves as both a physical barrier to commensal microbes 
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and an important component of the immune system. The intestinal epithelium is 
covered by a single layer of IECs, including enterocytes, goblet cells, paneth cells, 
endocrine cells and M cells, which work together to maintain homeostasis within the 
gut. These cells, originating from pluripotent intestinal epithelial stem cells, make up 
part of the mucosa, one of the four main vertical layers of the intestine8. Within the 
mucosa, IELs, predominately CD8+ T cells, are interspersed throughout and in direct 
contact with the epithelial cell layer as illustrated in Figure 1; this puts them along 
with the IECs at the forefront of the intestinal immune response. As part of the 
mucosa, the lamina propria, which lies beneath a basal membrane or thin layer of 
connective tissue under the IEC and IEL layer, is formed by a network of loose 
connective tissue that defines a compartment for heavily infused circulating immune 
cells, particularly T lymphocytes, macrophages, plasma cells, eosinophils, and mast 
cells8.  These immune cells are less frequently within the submucosa, the second 
layer of the intestine, since a thin smooth muscle layer called the muscularis 
mucosa8, a facilitator in movement and mucosal folding, acts as a divider between 
the mucosa and the submucosa8,9.  Within the submucosa lie larger vessels of the 
blood and lymphatic systems, nerve fibers and ganglia supported by loose fibrous 
connective tissue. Surrounding the submucosa is the muscularis propria that 
consists of two layers of smooth muscle that function in contractility of the gut9.  The 
outer most layer of the intestine is the serosa, a thin layer of loose connective tissue 
that connects to outer muscularis8,9. Throughout the intestine, there are widely 
dispersed gut-associated lymphoid tissues (GALT), such as Peyer’s patches in the 
  10 
small intestine and colonic patches and isolated lymphoid follicles in the large 
intestine, which are organized aggregates of immune cells mediating mucosal 
adaptive immune responses9-11. 
The epithelial tissues of the intestine undergo specific programs of self-renewal 
such that new cells are created every 10 to 14 hours from a dividing intestinal stem 
cell population, capable of differentiation while migrating from the crypt to the tip of 
the villus.  As the cells continue to migrate toward the tip, they undergo apoptosis 
such that the layer of epithelium is regenerated every three to five days in a human 
and every two to three days in mice.  The exceptions are Paneth cells in the small 
intestine and enteroendocrine cells, which are renewed less frequently, four weeks 
and 35-100 days, respectively8,9. A large portion of pluripotent intestinal  stem cells 
differentiate into  absorptive enterocytes while smaller specialized lineages include 
secretory enteroendocrine, goblet and Paneth cells.  Enteroendocrine cells, 
neuroendocrine regulators in the intestine, secrete several hormones needed for 
proper digestion. Goblet cells are major producers of mucin proteins, especially 
mucin 2, which form a mucous layer over the mucosa.  Goblet cells also produce 
proteins such as Trefoil factor 3, a protein that provides structural support for 
mucous layer integrity and signals the promotion of epithelial cell repair mechanism. 
Trefoil factor 3 together with muc2 adds additional level of protection against 
intestinal pathologic microbial stimuli. Paneth cells at the base of the crypt of the 
small intestine release antimicrobial molecules in larger quantities and variety than 
that of absorptive enterocytes.  Whereas enterocytes secrete the C-type lectin 
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REGIII gamma, which targets destruction of peptidoglycan walls of gram-positive 
bacteria, Paneth cells secrete defensins, lysozymes, and cathelicidins which defend 
against broader groups of bacteria. By way of active transcytosis, IECs also facilitate 
the release of antibodies, particularly IgA produced by lamina propria plasma cells, 
into the lumen. This joint effort between plasma cells and IECs maintains 
homeostasis by regulating microbial populations in the luminal compartment12.  
IECs also have the ability to sample antigen from within the lumen.  While it has 
traditionally been thought that epithelial microfold cells or M cells uniquely had the 
ability to engulf and transcytose microbial antigens into the Peyer’s patches, a recent 
study has reported that goblet cells can function similarly, transporting antigen to 
lamina propria dendritic cells12,13. Intestinal dendritic cells that are in direct contact 
with IECs are also capable of sampling antigens directly within the lumen by using 
their dendrites that can cross the epithelial monolayer.  It is not yet well understood 
how these different ways of antigen sampling functionally impact immune responses, 
but it is speculated that the different antigen-sampling cells may direct different types 
of immune responses12. 
In addition to mediate digestive process via digestive enzyme production, nutrient 
absorption, and antimicrobial peptide secretion, the IECs can actively sense 
commensal bacteria and pathogens and secrete cytokines and chemokines that are 
important for protective immunity and homeostasis of the intestine14. Recognition of 
microbe-associated molecular patterns by the IECs relies on the expression of a 
variety of pattern recognition receptors (PRRs), including toll-like receptors (TLRs), 
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RIG-I like receptors (RLRs) and nucleotide-oligomerization domain (NOD) like 
receptors (NLRs). Until recently, the focus of PRR studies has been on their role in 
eliciting a proinflammatory response in hematopoietic cells.  However, it is 
increasingly clear that the PRRs of IECs play an important role in facilitating immune 
tolerance to commensal microbiota and maintaining intestinal immune 
homeostasis12.  A major role of the IECs is to prevent invasion by the commensal 
bacteria, although it is also likely that IECs may interplay with immune cells to 
directly participate in immune tolerance. In this regard, several types of immune cells 
contribute to the establishment of immune tolerance to commensals and 
maintenance of immunosuppressive environment in the gut; these include IELs, 
regulatory T cells, and intestinal macrophages. These immunosuppressive cells are 
designed to promote a tolerogenic response and prevent active inflammation in 
response to nonthreatening commensals in the lumen or harmless antigen from the 
diet11,14 15.  
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Colorectal cancer pathology  
It is widely recognized that CRC develops in a stepwise fashion driven by 
accumulated genetic alterations and environmental factors.  Genetic mutations in 
intestinal stem cells may result in deregulation of growth- or survival-related 
signaling events, thereby altering homeostatic conditions that lead to formation of 
aberrant crypt foci, in which crypts appear to be larger than normal16,17.  These 
putative precancerous lesions are believed to eventually form gastrointestinal 
neoplasia (GIN) or microadenomas, microscopic areas of dysplasia. The continuous 
growth of these lesions results in the formation of macroscopic polyps termed 
macroadenoma or adenoma for short, characterized by grossly visible dysplastic 
epithelium that have not invaded through the muscularis mucosae16,17.  
Advancement of the adenoma growth through the muscular mucosae renders it an 
adenocarcinoma, the malignant and thus deadly stage of disease (Figure 1).  
Apc mutant animal models for the study of CRC 
Although the exact etiology for CRC is still elusive, several genetic mutations, 
both somatic and germline, as well as epigenetic changes have been linked to the 
development of this malignancy. In particular, patients with familial adenomatous 
polyposis syndrome (FAP) inherit a germline mutation in adenomatous polyposis coli 
(APC) gene in one allele.  The loss of the second allele occurs within 30 years.  As 
APC functions as a negative regulator of the Wnt signaling pathway, it controls the 
level of the active transcription factor β-catenin. The loss-of function mutation in the 
APC gene leads to accumulation of β-catenin within the nucleus, causing 
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uncontrolled induction of Wnt target genes and aberrant division of intestinal stem 
cells and IECs to form pre-cancerous cells and develop into microadenomas and 
adenomas16. Somatic mutation in APC is also commonly found in those with 
sporadic disease where the inactivation of APC gene occurs over time as a result of 
environmental exposures18.  
One of the first animal models of CRC was a randomly mutagenized mouse, 
carrying a mutation in the Apc gene that leads to expression of truncated form of 
APC protein19. The mutant mice spontaneously develop multiple intestinal neoplasia 
in the small intestine of the mice, from which the name Apcmin was given.  While this 
first model involves Apc truncating mutation at codon 850, subsequent knock in 
mutations to introduce Apc truncations at codon 716 or 1638 resulted in a similar 
phenotype. The variation in truncating sites in the Apc gene was performed to test 
whether the shorter truncation in the Apcmin/+ model as compared to those seen in 
human patients altered the observed phenotype.  Most of the various Apc truncating 
mutations resulted in overall similarity with polyp formation predominately in the 
small intestine of the mice except in a model where a frameshift at codon 1309, 
where polyps were distributed throughout the small intestine and colon, which more 
closely resemble the phenotype in patients who have colonic polyps as a result of 
APC LOH20.  However, the Apcmin/+ model continues to be the primary model used in 
studies seeking to identify additional genes involved in intestinal tumorigenesis.  
Though the small intestine is the predominant location for adenoma formation in the 
Apcmin/+ mice, polyps form in the colon but less frequently21.  However, high numbers 
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of microadenomas can be found in the colon of Apcmin/+ mice, which resemble those 
of the small intestine in that LOH of Apc and β-catenin nuclear accumulation are 
evident22.  The Apc716 model demonstrated that the LOH of the Apc allele in 
proliferating cells located at the base of the crypt is the initiating step to aberrant 
crypt foci or early lesions in the mucosa21. Mice homozygous for the mutant Apcmin 
die during embryogenesis22. Additional evidence of APC interaction with 
microtubules and Rac-specific guanine nucleotide exchange factor Asef to regulate 
actin cytoskeletal rearrangement and cellular morphology supports the idea that 
APC is needed for proliferating cells to travel to the tip of the villus.  Thus, the loss of 
APC in these cells would result in reduced Asef activity and decreased capacity to 
move and shed. Furthermore, APC interaction with proteins Asef2 and IQGAP1 also 
was reported to effect cell migration and polarity21. Additionally, mice heterozygous 
for Apcmin have displayed a gradual reduction in immature and mature T cells in the 
thymus and in immature and progenitor B cells in the bone marrow as well as a 
depletion of natural killer cells in the spleen.  Further bone marrow transplant 
experiments revealed that this phenotype was due to an aberration in the 
nonhematopoietic compartment of the bone marrow of Apcmin/+ mice as a result of 
decreased mesechymal progenitor cell population where single mesenchymal 
precursors derived from Apcmin/+ mice displayed less colony forming units than that 
of wildtype mice23. 
The inability to maintain mucosal immunological homeostasis could influence 
the outcome of polyp formation in this model.  In fact, not long after this study, 
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another group from MIT found that transferring wildtype CD4+CD25+ lymphocytes 
into the Apcmin/+ mice lessened tumor burden24.  Based on these two studies, one 
could speculate that the depletion of thymocytes as Apcmin/+ mice age may result in 
reduced regulatory lymphocyte populations in the periphery tissues, specifically the 
small intestine where the maintenance of tolerance is compromised. By transferring 
CD4+CD25+ lymphocytes from interleukin (IL)-10 knockout mice, this study further 
showed that the IL-10 production by CD4+CD25+ cells was necessary for enhanced 
cellular apoptosis and diminished expression of cyclooxygenase- (COX-) 2 and 
proinflammatory cytokine genes within polyps of the Apcmin/+ mice24. A paper 
published in 2012 reported increased expression of several proinflammatory 
cytokines, including TNF-α, IL-6, and IL-1β, in the small intestine of older Apcmin/+ 
mice as compared to young Apcmin/+ mice, which is positively correlated with 
abundance of large polyps25. While the authors of this publication did not compare 
the levels of these proinflammatory mediators to wildtype animals, one could 
speculate that the loss of APC affects immunosuppressive mechanisms in the small 
intestine of the Apcmin/+ mice which may lead to a proinflammatory environment that 
favors the formation and growth of polyps. 
The Apcmin/+ model has been used to identify several key players in the 
promotion and inhibition of intestinal adenoma development. Of particular 
importance is the proinflammatory enzyme COX-2, whose ablation reduces polyp 
formation in the Apcmin/+ model.  Furthermore, Cox-1 mutation in Apcmin/+ mice also 
causes reduction in polyp formation, similar to that of Cox-2 deficiency.  Further 
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studies demonstrate that both COX-1 and COX-2 stimulate angiogenesis in polyps 
by generating prostaglandin E2 (PGE2). COX-2 is expressed in both adenomatous 
polyps and malignant tumors and is now considered a common feature of tumors of 
the intestine. As a result of the findings from basic research, a COX-2 inhibitor, 
Celecoxib, has been developed and shown to significantly reduce the number of 
polys in FAP patients after six months of treatment26. However, some of the patients 
with sporadic disease treated with the COX-2 inhibitor in a later clinical trial suffered 
from cardiovascular side effects from the drug.  As a result, physicians prescribing 
nonsteroidal anti-inflammatory drugs to patients must consider their level of risk for 
cardiovascular side effects and proceed with careful medical supervision21. In 
addition to Cox-2, the BubR1 and Cdx2 genes were identified as regulators of 
genomic stability in the Apcmin/+ and Apc716 models, respectively.  Mutations in 
these genes resulted in higher numbers of intestinal polyps and rates of 
chromosomal instability in each respective model. The Apc models of CRC also 
gave insight into the effect of diet and exercise on the progression of disease.  
These models demonstrated that high fat diets accelerate with polyp formation while 
calorie-restricted diets significantly reduced polyp numbers. Exercise has also been 
shown to reduce polyp burden in the Apcmin/+ model, suggesting the need for dietary 
and exercise considerations in overall management of disease21.  
Apc mutant mice typically display only the formation of benign intestinal 
polyps that rarely advance to malignancy.  This model was useful in identifying the 
gene Smad4 as a player involved in progression of adenoma to adenocarcinoma. 
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Consistent with the involvement of Smad4 in TGF-β signaling, mice with Smad4 
deficiency in the Apcmin/+ background display similarities to patients with colon 
cancer associated with TGF-β type II receptor mutations21.  Phosphatidylinositol 3-
kinase (PI3K)/Akt pathway has also been associated with colorectal cancer.  Apcmin/+ 
mice with heterozygous mutation in the gene encoding PTEN, a negative regulator of 
PI3K pathway, development large invasive adenocarcinomas21. Similarly, invasion of 
polyps into the muscularis mucosae was observed in about half of a group of 
Apcmin/+ mice with Ephb3 homozygous gene knockout22. 
Additional mouse models exist such as β-catenin mutant mouse model in 
recapitulating inherited disease syndromes which are less frequently used, likely due 
to greater percentage of sporadic colorectal patients, approximately 80 percent, who 
possess the Apc gene mutation as compared to 10 percent who carry mutation in β-
catenin gene21,27.    
Inflammation and colon cancer 
 There was an early suggestion linking inflammation to cancer in the 19th 
century when pathologist Rudolf Virchow predicted that chronic inflammation and 
irritation may be a key player in cancer, an idea that was largely ignored as the main 
scientific focus was on intrinsic events within the premalignant cells that drive cancer 
development28,29. Most recently, many studies have provided evidence in support of 
the idea that cancer can evade immune destruction and is also stimulated by some 
inflammatory mediators or inflammatory disease conditions16,28.  Now both cancer 
immune evasion and chronic inflammation have been included as hallmarks of 
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cancer30. Epidemiological studies over the last fifteen years have revealed an 
estimate of about 20 percent of cancer deaths occur in the context of inflammation 
and infection28.  The idea of linking tumor formation and inflammation is particularly 
important in the intestine, where inflammatory disorders have been associated 
colorectal cancer.  Increased risk for CRC has been observed in patients with 
chronic inflammatory diseases of the intestine, such as ulcerative colitis or chronic 
inflammatory bowel disease31.  In fact, about 20 percent of patients with IBD develop 
colitis-associated cancer, a subtype of CRC that is fatal in more than 50 percent of 
these cases16. It has also been shown that an inflammatory component is involved in 
other types of CRC that lack grossly visible inflammation but have immune cell 
infiltrates and proinflammatory cytokine production within intestinal polyps16. In fact, 
the advancement of adenoma development in Apcmin/+ mice correlates with 
increased expression of proinflammatory mediators (Figure 2). As mentioned in a 
previous section, the use of the Apcmin/+ model identified that loss of Cox-2, an 
enzyme involved in promoting inflammation, reduced polyp numbers in the small 
intestine of mice.  Similarly, Cox-1 inhibition caused the same, suggesting that 
mediators of inflammation are involved in tumor development 16,21,31.  
Regulation of inflammation and cancer by IL-10 
One distinct feature of mucosal immunity as it compares to nonmucosal forms 
is that T cells of the gut have an activated or memory effector phenotype. They are 
poised for rapid induction of inflammation via cytokine production when necessary, a 
state that is tightly regulated by effector regulatory T cells in this environment that 
  20 
are poised to suppress inflammation.  These two mechanisms coexist, but the 
immunological environment at mucosal surfaces tends to be a default program of 
immunosuppression or tolerance. The T cells are designed to prevent active 
inflammation in response to commensals, which continuously interact with the 
surrounding epithelia32,33.  
One cytokine identified to have anti-inflammatory properties is IL-10. IL-10-
deficient mice developed enterocolitis in the duodenum, jejunum, and colon, 
characterized by significant growth retardation and ultimately death.   However, the 
inflammatory conditions of the Il10 knockout mice were greatly attenuated when they 
were housed under specific pathogen free conditions, suggesting that IL-10 
suppresses the immune response to intestinal antigens 34. Il10 receptor knockout 
mice exhibited a similar phenotype, supporting the role of IL-10 in intestinal 
homeostasis35.  
Furthermore, Il10 knockout weanlings, the age where gastrointestinal normal 
flora begin colonization, exhibited early signs of focal inflammatory lesions in the 
intestine which progresses to transmural inflammation, epithelial hyperplasia and 
then adenocarcinoma with age. Increased levels of proinflammatory cytokines, such 
as TNF-α, IL-6, IL-1β and IFN-γ, were present in the colons of IL-10 deficient mice 
as compared to wildtype mice.  These sequelae were prevented in weanlings of Il10 
knockout mice who were treated with IL-10 intraperitoneally. While IL-10 had no 
statistically significant effect on the inflammation of adult mice, the IL-10 treatment 
did reduce the incidence of adenocarcinoma36.  These early findings suggest that IL-
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10 is required for maintaining intestinal homeostatic conditions and that its loss 
promotes intestinal inflammation and colorectal cancer. Further observations that 
colitis did not develop in IL-10-deficient mice treated with antibiotics or raised in a 
germ free environment corroborated these conclusions, demonstrating the role of IL-
10 in suppressing immune cell reaction to intestinal microbiota37.   
A study using Il10 green fluorescent protein (GFP) reporter mice 
demonstrates that CD8+ intestinal epithelial lymphocytes (IELs) and CD4+ 
lymphocytes in the lamina propria cells are the major cells expressing IL-1038.  In the 
same study, in vivo stimulation of IELs from the small intestine with anti-CD3 
demonstrated that these cells were programmed to be IL-10 producing cells. 
Similarly, anti-CD3 stimulation of lamina propria lymphocytes induced a regulatory 
phenotype where GFP expression was observed.  Both Foxp3+ Treg cells and IL-
10-producing cells are responsible for homeostatic maintenance in the lamina 
propria while Foxp3- IELs assume this role in the epithelium demonstrated by IL-10-
expressing GFP+ populations. Adoptive transfer of splenic CD4+ T cells to 
immunodeficient mice demonstrated that the gut microenvironment contributes to 
this phenotype where transferred cells found in the IEL compartment exhibited GFP 
expression after stimulation while those recovered from the spleen did not38. 
Furthermore, adoptive transfer of TCRαβ subpopulation of intestinal IEL into severe 
combined immunodeficiency mice prior to the induction of chronic colitis 
demonstrated that intestinal IELs suppress intestinal inflammation in an IL-10-
dependent manner39.  
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TBK1 structure and regulation  
The serine/threonine protein kinase TBK1 is involved in several signaling 
pathways such as immune response to pathogen recognition, autophagy, cell 
survival and growth and oncogenesis40.  Because of its molecular structure, its 
ubiquitous expression pattern, TBK1 is thought to serve as an important signal 
transducer, connecting various upstream signals to downstream biological 
processes40. It possesses a catalytic kinase domain (KD) at its N-terminus that 
interacts with its ubiquitin-like domain (ULD) and alpha helical scaffold dimerization 
domain (SDD) (Figure 3)41,42.  Nearly full-length x-ray crystallography and TBK1 
protein purification revealed that TBK1 exists in an homodimer conformation where 
KD are outward on opposite sides of the complex in the inactive form41,42. KD and 
SDD are conjugated with K63-linked ubiquitin chains at Lys 30 and Lys 401, 
respectively, which is a necessary modification for its activation43. An x-ray crystal 
structure from another group revealed that the KD of the active form of TBK1 is 
repositioned to perform its catalytic functions while remaining in dimer formation and 
keeping the C-terminus domain (CTD) facing away from the main body of the dimer. 
This configuration also allows for trans autophosphorylation between TBK1 dimers, 
resulting in phosphorylation of Ser172 in the activation loop of the KD domain41.  In 
addition to mediating homodimerization of TBK1, the SDD also is required for 
substrate phosphorylation and has been speculated to facilitate adaptor protein 
recruitment needed for regulating substrate specificity43,44. Dimerization is not 
required, however, for adaptor protein interactions41.  The CTD has been described 
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as an adaptor-binding motif involved in the recruitment of TBK1 to various other 
signaling mediators45.  The adaptor-binding motif of TBK1 allows it to interact with a 
variety partners to transduce a signal within a cell40.  Furthermore, adaptor proteins 
containing ubiquitin domains can bind to TBK1 via polyubiquitin chains, but the 
specificity of TBK1 binding to its substrates is likely dependent upon its cellular 
localization40,46.  Cellular localization of TBK1 also regulates its activation by different 
stimuli. In response to upstream signals, TBK1 is recruited, by adaptor proteins, to 
specific signaling complexes, in which the concentrated TBK1 may be activated by 
autophosphorylation or phosphorylation by upstream kinases40.  TBK1 also contains 
leucine zipper and helix-loop-helix motifs within the SDD region, although functions 
of these motifs are less well defined45. 
A major class of TBK1 stimuli is the pathogen-associated molecular patterns 
(PAMPs), which are components of various microorganisms such as DNA, single- 
and double-stranded RNA, and surface glycoproteins. PAMPs initiate innate immune 
responses through stimulation of pattern recognition receptors (PRRs). Several 
PRRs are able to target the activation of TBK1 and induce type I interferon 
production; these include the TRIF-dependent TLRs (TLR3 and TLR4), the NLR 
member NOD2, the intracellular RNA sensor RIG-I, and the intracellular DNA sensor 
STING. The activation and signaling function of TBK1 involve its recruitment to the 
PRR adaptors, such as TRIF (TLR/IL-1R domain-containing adaptor protein inducing 
IFN-β), MAVS (mitochondrial antiviral signaling proteins), and STING (stimulator of 
IFN genes).  Upon activation by the PRRs, TBK1 phosphorylates IRF3, triggering the 
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dimerization and nuclear translocation of this anti-viral transcription factor and 
allowing IRF3 to induce expression of the type I interferon genes (Figure 3)47.  While 
IRF3 is the most widely recognized substrate of TBK1, many others have been 
identified, including the interferon-responsive transcription factor IRF7, NF-κB 
members (p65 and c-Rel), signaling adaptors (TANK, MAVS, STING, and TRIF), 
kinases (NIK, AKT, IKKα, IKKβ, and NEMO), E3 ubiquitin ligases (PELI1 and XIAP), 
autophagy receptors (OPTN and p62), and the exocyst component Sec 5 in RalB 
signaling40,48,49.  
As seen with other kinases, TBK1 activation is subject to control by negative 
regulators. One such TBK1 regulator is protein phosphatase Mg2+/Mn2+-dependent 1 
B (PPM1B or PP2Cβ), which binds and dephosphorylates TBK1 at Ser172 and, 
thereby, inhibits virus-induced IRF3 phosphorylation and IFN-β expression50.  
Inositol 5’ phosphatase SHIP1 (Src homology 2 domain-containing protein tyrosine 
phosphatase 1) has also been implicated as a negative regulator of TBK1; SHIP1 
deficiency in macrophages resulted in hyperphosphorylation of TBK1 even under 
unstimulated conditions and TLR3-stimulated IFN-β production51.  The authors 
though did not present evidence describing the mechanism and therefore it remains 
unknown whether SHIP1 directly or indirectly regulates TBK1 activity. Another 
phosphatase, SHIP2, inhibits TBK1 activation and IFN-β production by directly 
binding to the N terminal KD region of TBK1 and acting independently of the 
phosphatase activity of SHIP252.  
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As previously mentioned, ubiquitination of TBK1 plays an important role in its 
activation. Ubiquitin ligase Nrdp1 directly binds and polyubiquitinates TBK1 in 
macrophages after TLR stimulation, leading to IRF3 activation47.  Conversely, the 
function of TBK1 is negatively regulated by deubiquitinases, proteases that cleave 
ubiquitin chains. The deubiquitinase CYLD has been shown to interact with TBK1 
and removes K63-linked ubiquitin chains from it, resulting in reduced TBK1 kinase 
activity and IRF3 phosphorylation as well as downregulated type I IFN 
expression53,54.  A20 is another deubiquitinase known to regulate TBK1 activation. 
A20 functions as a ubiquitin-editing complex, composed of A20, Tax1 binding protein 
1 (TAX1BP1), and A20 binding inhibitor of NF-κB 1 (ABIN1), which negatively 
regulates TBK1 activation antiviral response by disrupting the association of TBK1 
with its upstream activator TRAF347.  A similar function has also been demonstrated 
for the RING Finger Protein 11 (RNF11), which binds to TBK1 via TAX1BP1 and 
inhibits TBK1 activation and virus-induced IFNβ expression by blocking the 
association of TBK1 with TRAF3 and TBK1 K63 ubiquitination55.  TBK1 is also 
negatively regulated through K48 type of ubiquitination, which targets TBK1 for 
proteasomal degradation, an event typically observed at longer time points likely 
involved in the resolution of a viral induced-inflammatory response.  E3 ligases 
DTX4 and TRIP have been identified as mediators of this process47. 
 TBK1 as a mediator of multiple signaling pathways  
 TBK1, also termed T2K56 or NAK (NF-κB-activating kinase), was initially 
identified in a two-hybrid screen as a protein that interacts with TANK, a regulator of 
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NF-κB signaling pathway, and was proposed by Joel Pomerantz and David 
Baltimore at that time to mediate TANK-dependent NF-κB activation18,57. Tbk1 
deletion in mice results in embryonic death due to liver apoptosis and failure, a 
phenotype similar to mice deficient in other mediators of the NF-κB signaling 
pathway56,58. TBK1 was initially thought to serve as an upstream kinase of the 
classical IkB kinase (IKK) IKKβ; however, later studies demonstrated a dispensable 
role for TBK1 in the activation of IKK and NF-κB57,58. It is now clear that the 
canonical function of TBK1 is to phosphorylate and activate IRF3, mediating type I 
interferon induction during viral infection58. However, more recent studies have led to 
the identification of additional targets of TBK1 in various other signaling pathways. 
For example, TBK1 mediates CD40 and BAFF receptor-induced NIK degradation 
and negatively controls noncanonical NF-κB activation, a function that is crucial for 
maintaining normal production of the antibody IgA48. TBK1 also mediates proteolysis 
of AKT and negatively regulates the activation of the metabolic kinase mTORC1 by 
T-cell receptor, thereby modulating the activation and migration of T cells.59 In 
cancer cells, TBK1 may play a role in mediating the expression of survival genes 
through activation of NF-κB family members, such as c-Rel and p6545,60. It is 
anticipated that additional signaling targets of TBK1 will be identified in normal and 
cancer cells.  
TBK1 in the regulation of immune responses  
Although TBK1 is expressed ubiquitously in numerous cell types, much of 
our knowledge about its functions comes from studies involving cells of the immune 
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system. It is well supported by both in vitro and in vivo studies that activated TBK1 
targets IRF3 and IRF7 for phosphorylation and activation in response to TLR or 
nucleic acid sensor stimulation, resulting in the production of type I interferons 
necessary for an antiviral response (Figure 4).  TBK1-mediated IRF3 regulation is 
also essential for preventing de novo viral replication in vivo58.  
Using B cell-conditional Tbk1 knockout mice, our laboratory has revealed a 
new role for TBK1 in negatively regulating IgA antibody class switching by targeting 
the phosphorylation and degradation of NF-κB-inducing kinase (NIK), a key mediator 
of the noncanonical NF-κB signaling pathway48. The B cell-conditional Tbk1 
knockout mice had elevated levels of serum IgA and autoantibodies as well as 
antibody deposition to the kidney glomeruli, associated with nephropathy-like 
symptoms. Upon stimulation by some of the IgA inducers, such as stimuli of CD40 
and BAFF receptor, the TBK1-deficient B cells have hyper-activation of noncanonical 
NF-κB as a result of increased NIK protein level. Thus, TBK1 controls the fate of NIK 
and the magnitude of noncanonical NF-κB activation in B cells to modulate antibody 
responses48 (Figure 5).  
TBK1 also plays a role in regulating T-cell activation and migration59. Mice 
with T cell-specific Tbk1 ablation have increased frequency of T cells with activated 
effector- or memory-like surface markers, indicative of aberrant activation under 
homeostatic conditions. However, in a central nervous system (CNS) autoimmune 
inflammation model, the TBK1-deficient effector T cells display a defect in migration 
from the draining lymph nodes to CNS. Consequently, the T cell-conditional Tbk1 
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knockout mice are refractory to the induction of experimental autoimmune 
encephalomyelitis, an animal model for human multiple sclerosis. While previous 
studies suggest a role for TBK1 in activating AKT via direct phosphorylation and 
promoting human cancer cell survival49,61,62, genetic ablation of Tbk1 in T cells 
unexpectedly causes enhanced activation of AKT and its downstream target 
mTORC148,60,6159. It appears that TBK1-mediated AKT phosphorylation serves as a 
trigger for AKT degradation (Figure 6). Ablation of one allele of Akt, to reduce its 
level of expression in TBK1-deficient mice, restores the ability of their T cells to 
migrate to CNS and renders them sensitive to EAE induction59. 
TBK1 in autophagy 
The process of autophagy occurs as a means to recycle damaged proteins or 
cellular organelles in order to generate energy for the cell or to remove a molecular 
threat during starvation states.  Autophagy can also occur in response to microbial 
infection as part of an innate immune response where an autophagosome forms 
around the bacteria to prevent their replication and possibly induce their destruction. 
This process involves ubiquitination of intracellular bacteria, a modification that 
recruits the Ubiquitin-binding autophagic adaptor protein optineurin (OPTN) and, 
thereby, triggers the assembly of the autophagic machinery. TBK1 has been 
implicated as an important regulator of autophagy responses to bacterial infections, 
in which TBK1 acts by phosphorylating OPTN and promoting its interaction with 
autophagic components, particularly Atg863.  Additional studies suggest that TBK1 
also promotes the maturation of the autophagosome in macrophages during 
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bacterial infection by phosphorylating the autophagy adaptor sequestosome 1 (also 
called p62), which facilitates bacterial clearance32. These findings demonstrate 
another mechanism of action for TBK1 in the regulation of immune responses. 
TBK1 in oncogenesis  
One of the first clues of TBK1’s potential involvement in cancer was 
presented in 2006 by the groups of Ulrich Brinkmann and Ira Paston who performed 
a high throughput screening using various cDNA expression libraries that revealed a 
potential role for TBK1 and IRF3 in regulating angiogenesis64. Overexpression of 
TBK1 or its target transcription factor IRF3 induce secreted factors that promote the 
proliferation of human umbilical vein endothelial cells (HUVEC), a frequently used 
marker for the study of angiogenesis. In line with this finding, TBK1 expression is 
induced under hypoxic conditions64, a physiological state within tumor 
microenvironment that promotes angiogenesis within solid tumors65. Some solid 
tumors, such as human breast and colon cancer, have been shown to have 
upregulated TBK1 expression, although the significance of this finding warrants 
further studies since the data are quite variable among cancer patients64. 
Shortly thereafter, Michael White’s group reported that TBK1 downregulation 
by RNAi promotes apoptosis in HeLa, PANC-1 and MCF7 human cancer cell lines in 
vitro through its activity downstream of the Ras-like protein RalB66.  RalB, a kinase 
implicated in tumorigenesis-associated processes45,67,68, can activate TBK1 in vitro, 
signaling its interaction with downstream Sec proteins of the exocyst44,66,6766.   This 
sequence of events is needed for the induction of oncogenic transformation by 
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Ras45,66.  Specifically, TBK1-deficient mouse embryonic fibroblast (MEF) cells could 
not undergo transformation and eventually died after retroviral infection with mutant 
KRASG12V as compared to wildtype MEFs that were transformed and grew in 
culture66. A few years later, William Hahn and Tyler Jack’s group performed a screen 
in 19 cell lines that possessed either KRAS wildtype or mutant gene using RNA 
interference libraries targeting cell signaling mediators such as protein kinases, 
phosphatases and oncogenes. The screen revealed TBK1 as a synthetic lethal 
partner in KRAS mutant human lung cancer cell lines.  Specifically, this paper 
showed that in vitro downregulation of TBK1 using short hairpin (sh) RNAs resulted 
in decreased cell survival of lung cancer cells dependent upon KRAS. Additional 
experiments from this paper showed that knockdown of TBK1 in KRAS mutant 
human lung cancer cell lines resulted in decreased tumor size over time in xenograft 
models using immunocompromised mice while human lung cancer lines exhibiting 
wildtype KRAS exhibited either increase or no difference in xerograph tumor growth 
after TBK1 downregulation as compared to mice injected with GFP shRNA control60.   
The data from these high profile papers led to advanced studies in delineating 
mechanisms by which TBK1 promotes survival in human cancer cell lines.  Using in 
vitro models, TBK1 was found to engage with and activate AKT after KRASG12V 
transformation in a stimulant-dependent and -specific manner, thus promoting tumor 
cell survival 62. It has also been suggested that TBK1 promotes human lung cancer 
cell survival through its regulation of autophagy, a cellular process that involves the 
lysosomal degradation of intracellular organelles and proteins to generate 
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macromolecules needed for cell survival and metabolism during starvation or to 
maintain intracellular integrity of proteins and organelles for proper functioning69,70. 
Similar to previous models, TBK1 knockdown in A549 human lung cancer cells using 
RNA interference in vitro resulted in reduced punctate accumulation of microtubule-
associated protein 1B light chain 3 (LC3B), an autophagosomal indicator of 
autophagy induction, which was associated with reduced nuclear translocation of 
RelB using immunofluorescent imaging.  The authors proposed a model that TBK1 
participated in the autophagic process in KRAS mutant human lung cancer cells thus 
leading to non-canonical NF-κB signal induction promoting cell survival or 
proliferation69, although direct evidence is lacking for the latter.  It is also remains 
unclear how autophagy is directly regulated by TBK1 in this model.   
With the use of quantitative mass spectrometry as an approach to study 
protein phosphorylation, Eric Haura’s research team identified over 2000 alterations 
in phosphorylation in nearly 400 proteins after TBK1 knockdown in human A549 lung 
cancer cell line71.  From this large number, the authors focused on diminished 
phosphorylation observed in the mitotic regulator polo-like kinase (PLK) 1 after TBK1 
RNAi.  In vitro assays demonstrated that TBK1 binds to and phosphorylates PLK1 at 
Thr-210 during mitosis.  In addition, the authors determined a correlation between 
cell viability after TBK1 knockdown and cell viability after PLK1 pharmacological 
inhibition71. While the authors independently confirmed previous reports that TBK1 
knockdown in A549 cells reduces cell viability and separately demonstrated that 
treatment of lung cancer cells in vitro with PLK1 inhibitors decreased cell survival, it 
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remains to be determined whether TBK1-mediated PLK1 phosphorylation has a 
direct link with cancer cell survival71.   
While the study of the role of TBK1 in cancer has so far focused on KRAS-
dependent lung cancer cells, a more recent work examined TBK1 using human 
breast cancer cell lines and suggested the involvement of TBK1 in mediating breast 
cancer resistance to tamoxifen treatment72.  TBK1 binds and phosphorylates 
estrogen receptor alpha (ERα) at serine 305 in MCF7 breast cancer cell line, thereby 
affecting ERα’s transcription activity. RNAi-mediated TBK1 silencing in MCF7 cells 
results in slower growth of the cell line, whereas TBK1 overexpression in MCF7 cells 
renders the cells more resistant to tamoxifen treatment.  Immunohistochemical 
analyses revealed elevated expression of TBK1, as compared to normal tissue, and 
positive correlation of TBK1 expression with the expression and Ser-305 
phosphorylation of ERα. The higher TBK1 expression is also associated with poorer 
disease-free survival in patients treated with tamoxifen, although this correlation is 
not seen in patients who are not treated with tamoxifen.  These findings suggest that 
TBK1 may have a role in mediating breast cancer tamoxifen resistance72.  
Despite the many studies that demonstrate the association of TBK1 with 
cancer, a more recent work failed to demonstrate the requirement of TBK1 in cancer 
cell survival by using large panel of human cancer cell lines and similar experimental 
approaches employed by the others73.  However, while the previous studies relied on 
a single or limited number of TBK1 shRNAs, this later study used six different TBK1 
shRNAs targeting different coding and 3’ untranslated regions. Although the TBK1 
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shRNA used previously (shT17) did reduce the viability of cancer cells, many other 
TBK1 shRNAs did not produce this phenotype, despite their high efficiency in TBK1 
knockdown. Furthermore, overexpression of TBK1 in the shT17-knockdown cells 
failed to rescue cell viability but restored the phosphorylation of IRF3, a primary 
substrate of TBK173. These results suggest the possibility that some of the previous 
observations may have been due to off-target effect of the TBK1 shRNAs. 
Consistently, treatment of cancer cell lines with three different TBK1 inhibitors 
efficiently inhibited IRF3 phosphorylation with only minimal effect on cell viability. 
Moreover, no correlation could be demonstrated between the degree of Ras activity 
in the cell lines and sensitivity to the inhibitors. Overall, the authors concluded that 
the growth or survival of KRAS-dependent cancer cell lines is not entirely TBK1-
dependent73; thus creating controversy regarding this topic and raising the questions 
of whether and how TBK1 regulates cancer development and whether its function 
depends upon the type of tumor.   
TBK1’s role in colon cancer is unknown 
A prior study revealed that colon tumor samples taken from patients display 
different patterns of TBK1 expression. Although some tumor samples have higher 
levels of TBK1 expression than normal tissue, some other tumor samples have 
greatly suppressed TBK1 expression64. These findings indicate the potential 
involvement of TBK1 in CRC pathogenesis. Of note, TBK1 is localized to human 
chromosome 12q14.174,75, a region associated with chromosomal abnormalities such 
as deletions, inversions, duplications, insertions, and translocations in pancreatic, 
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ovarian, skin, breast, and prostate cancers and pulmonary chondroid 
hamartomas73,7476-78. Similarly, one report identified chromosome 12q14.1 copy-
number losses in salivary duct carcinoma using a single-nucleotide polymorphism 
microarray platform79.  Of particular interest, putative shallow deletions and gains of 
TBK1 accounted for 20 percent and 30 percent of adenocarcinoma tissue samples 
sequenced from the large intestine of patients within validated and provisional 
datasets of The Cancer Genomics Atlas (TCGA) respectively80,81 (Figure 7).  The 
datasets are made publicly available through TCGA consortia using 
www.cbioportal.org that contain comprehensive large-scale genomic, transcriptomic 
and epigenomic profiling of various cancers including colorectal cancer 80,81. In 
addition, point mutations were found in TBK1 in nearly two percent of patient 
samples sequenced from adenocarcinoma tissues of the large intestine deposited in 
Catalogue of Somatic Mutations in Cancer (COSMIC) 82,83 (Figure 3; Table 2).  
These mutations were dispersed through all domains of TBK1 (Figure 3; Table 2), all 
of which are necessary for its specific function41-43,84.  Based on these findings, we 
hypothesized that TBK1 might play a role in intestinal tumorigenic processes in vivo, 
and we examined this hypothesis in this dissertation using a novel animal model. 
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Figure 1. Multiple factors play a role in colorectal cancer development.   
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Figure 1. Multiple factors play a role in colorectal cancer development.   
As a result of some genetic and/or environmental changes including hereditary and 
somatic mutations, injury and/or chronic inflammatory disease, aberrant crypt foci 
(ACF) form and accumulate within the intestinal epithelium. As abnormal cell 
signaling and diminished cellular protective functions such as DNA repair continues, 
adenomas form.  The disease advances to carcinoma when the adenomas invade 
through the basement membrane (BM) into nearby tissues and lymph nodes. This 
stage of development is driven by the accumulation of mutations and chromosomal 
abnormalities and altered microenvironment.  Advancement of the disease results in 
malignancy whereby cancer cells metastasize into distant tissues, organs and lymph 
nodes. Malignancy may result in death for patients with CRC. 
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Figure 2. Disruption of the immunological balance in the gut contributes to 
intestinal adenoma development. 
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Figure 2. Disruption of the immunological balance in the gut contributes to 
intestinal adenoma development.  Illustration of the relationship between intestinal 
tumorigenesis and inflammation.  Disruption of intestinal epithelial cell homeostasis 
during the initiation and progression of intestinal adenoma development alters the 
behavior of intestinal immune cells, which influences disease progression.  
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Figure 3. Structure of TBK1 indicating point mutations identified in 
adenocarcinomas sampled from CRC patients.  
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Figure 3. Structure of TBK1 indicating point mutations identified in 
adenocarcinomas sampled from CRC patients.  
Schematic of the structure of TBK1 indicating point mutations identified in almost two 
percent of 1,226 CRC patient tumor samples sequenced from adenocarcinoma 
tissues of the large intestine (deposited in Catalogue of Somatic Mutations in 
Cancer).  These mutations, including truncating mutations (*) and frame-shift (fs) 
insertions and deletions (del), were located in the kinase domain (KD), ubiquitin-like 
domain (ULD), the helical scaffold dimerization domain (SDD) and the C-terminal 
domain (CTD), all of which are necessary for proper function of TBK1. 
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Figure 4. TBK1 regulates type I interferon innate immune response. 
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Figure 4. TBK1 regulates type I interferon innate immune response. 
TBK1 mediates type I interferon expression upon PRR stimulation of innate immune 
cells by phosphorylating transcription factor IRF3. This leads to subsequent nuclear 
translocation dimerized IRF3 and activation of type I interferon gene expression. 
  
  43 
Figure 5. TBK1 negatively regulates noncanonical NF-κB signaling and IgA 
production in B cells.  
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Figure 5. TBK1 negatively regulates noncanonical NF-κB signaling and IgA 
production in B cells.  
In B cells, TBK1 negatively regulates IgA antibody class switching upon stimulation 
of TACI or BAFF receptor. TBK1 controls B Cell antibody responses by targeting the 
phosphorylation and degradation of NF-κB-inducing kinase (NIK), a key mediator of 
the noncanonical NF-κB signaling pathway. 
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Figure 6. TBK1 regulates T cell activation and egress from the lymph nodes by 
regulating AKT. 
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Figure 6. TBK1 regulates T cell activation and migration by regulating AKT. 
In T cells, TBK1 regulates T cell activation and egress from lymph nodes to the 
central nervous system under inflammatory conditions.  The TBK1 controls T cell 
migration from lymph nodes by targeting AKT for phosphorylation and degradation 
thus regulating downstream mediators such as mTORC1 involved in T cell egress. 
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Figure 7. Percentage of putative shallow deletion, diploid, gain and 
amplification of TBK1 copy-number identified in adenocarcinomas sampled 
from CRC patients profiled in validated and provisional datasets of TCGA. 
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Figure 7. Percentage of putative shallow deletion, diploid, gain and 
amplification of TBK1 copy-number identified in adenocarcinomas sampled 
from CRC patients profiled in validated and provisional datasets of TCGA. 
Putative shallow deletions gains of TBK1 accounted for 20 percent (top) and 30 
percent (bottom) of adenocarcinoma tissue samples sequenced from the large 
intestine of patients within validated (top) and provisional (bottom) datasets of The 
Cancer Genomics Atlas (TCGA) respectively.  The datasets are made publicly 
available through TCGA consortia using www.cbioportal.org.80,81 
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Chapter 3: Intestinal epithelial cell-specific TBK1 inhibits intestinal adenoma 
growth in Apcmin/+ mice  
Introduction 
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality 
whereby almost 150,000 people are diagnosed per year and approximately one-third 
of individuals will die from disease per year in the United States alone.  Worldwide, it 
affects almost 1.2 million people such that it is the third most common cancer 
diagnosed in women and men2,85.  Globally, almost 600,000 persons die from colon 
cancer each year, which makes it one of the leading causes of cancer-related deaths 
for men and women combined2.  Since the prognosis of CRC is still poor, it is critical 
to understand the process of intestinal tumor development and progression. 
It is generally believed that CRC development results from dysregulated 
signaling events in IECs, causing out-of-control growth and/or survival and 
subsequent transformation of these cells.  Several risk factors have been associated 
with CRC, including somatic and germline mutations, chronic intestinal inflammation, 
diet and lifestyle.  For example, when the normal epithelium of the gut encounters 
inflammation, environmental mutagens including reactive oxygen and nitrogen 
species, tissue damage and repair, and/or inherited mutations within the intestine, 
cellular signaling pathways are induced in order to maintain or return the gut to 
homeostatic state.  When these protective mechanisms are altered such that they do 
not properly function, adenoma formation eventually may occur and pose the risk for 
colorectal malignancies16,86. Understanding the biology and cellular mechanisms that 
  51 
are involved in this early stage process is important for improving the approaches for 
CRC prevention and treatment. 
The Wnt signaling pathway has been closely linked to the tumorigenic 
process in the gut. A central regulator of the Wnt pathway is the tumor suppressor 
adenomatous polyposis coli (APC), which functions by targeting the transcription 
factor β-catenin for proteolysis. Abnormal activation of the Wnt signaling pathway 
has been frequently observed in both hereditary and sporadic colorectal cancers and 
is often attributed to the loss-of-function mutations of APC or activating mutations in 
the transcription factor β-catenin87. A mouse model, Apcmin/+, has been frequently 
used in the study of CRC. The Apcmin/+ mice carry a heterozygous mutation in the 
Apc gene that leads to APC truncation19. This mouse model is particularly useful for 
the identification of novel factors involved in the regulation of intestinal 
tumorigenesis.   
The serine/threonine protein kinase TBK1 is involved in several signaling 
pathways such as pathogen recognition and immune response, inflammatory 
response and Ras-dependent oncogenesis40.  The current literature using human 
lung and breast cancer cell lines implicates TBK1 as having oncogenic activity60,66,72. 
Specifically, these in vitro studies and xenograft mouse models proposed that TBK1 
supports cell survival of KRAS-driven lung cancers and tamoxifen-resistant breast 
cancers60,66,72.  However, a more recent independent study challenged the 
conclusions of these studies, stating that TBK1 is dispensable for cancer cell 
survival73.  The in vivo function of TBK1 in regulating intestinal tumorigenesis has not 
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yet been explored.  By generating intestinal epithelial cell (IEC)-conditional Tbk1 
knockout mice, the present study addresses the role of TBK1 specifically in intestinal 
tumor development. Our work unexpectedly demonstrated a role for TBK1 to 
suppress intestinal tumorigenesis in the Apcmin/+ mice.   
Results  
IEC-specific Tbk1 ablation promotes adenoma formation in Apcmin/+ mice.   
To study the role of TBK1 in the gut, we generated IEC-conditional Tbk1 
knockout (hereafter called Tbk1IEC-KO) mice by crossing mice with Tbk1 loxP-flanked 
(floxed) alleles with mice expressing Cre under the control of villin promoter (villin-
Cre) (Figure 8A-C). Western blot demonstrates the loss of TBK1 protein from 
isolated primary IECs in the Tbk1IEC-KO (Figure 8C). The Tbk1IEC-KO mice appeared 
normal in growth and survival (data not shown). Based on gross examination, the 
IEC-specific Tbk1 ablation did not appreciably alter the number (Figure 8A) or size of 
Peyer’s patches in the small intestine. Histology analyses based on hemotoxylin and 
eosin (H&E) staining also did not reveal noticeable inflammation or tissue damage in 
the small intestines (Table 1) (Figure 9C and D).  
We next crossed the Tbk1IEC-KO mice with the Apcmin/+ mice to examine the 
role of TBK1 in regulating intestinal adenoma development (Figure 8D). Western blot 
demonstrates the loss of TBK1 protein from isolated primary IECs in the 
Apcmin/+Tbk1IEC-KO mice (Figure 8E).  Loss of TBK1 in IECs of Apcmin/+ mice resulted 
in increased polyp formation in the small intestines as compared to Apcmin/+ mice at 
four months of age (Figure 10A-B, D). Such a phenotype was detected in both the 
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distal and proximal regions of the small intestine of the Apcmin/+Tbk1IEC-KO mice, 
although the distal region had a more profound increase in the number of polyps 
(Figure 10B). These results suggest that the IEC-specific TBK1 plays a suppressive 
role in intestinal tumorigenesis.  In addition to polyp number, polyp size was larger in 
Apcmin/+Tbk1IEC-KO mice compared to age-matched (four months) Apcmin/+ mice 
(Figure 10C). The effect of TBK1 deficiency on adenoma size was observed mainly 
in medium-sized adenomas. At an older age (six months), the Apcmin/+Tbk1IEC-KO 
mice also formed large multifocal adenomas in the distal region of the small 
intestine, which was not observed in the control Apcmin/+ mice (Figure 10E).  These 
findings suggest a role for the IEC-specific TBK1 in negatively regulating the 
formation or growth of adenomas.  
Since the distal region of small intestine, covering the ileum, has more 
abundant Peyer’s patches and more diverse and abundant microbiota, we speculate 
that the promotion of tumor growth in this region might be due to the inflammatory 
nature of this environment, an idea which we are currently exploring.  
Young Apcmin/+Tbk1IEC-KO mice exhibit earlier polyp formation as compared to 
Apcmin/+ mice. 
To assess the mechanism by which TBK1 regulates intestinal adenoma 
formation, we examined whether the loss of TBK1 had an effect on the early stage of 
polyp formation. We analyzed the polyps in young Apcmin/+ and Apcmin/+Tbk1IEC-KO 
mice. Higher numbers of polyps were found in Apcmin/+Tbk1IEC-KO mice as early as six 
weeks of age (Figure 11A). However, the TBK1 deficiency did not significantly alter 
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the number of microadenomas (Figure 11B and C). Thus, it is likely that TBK1 
regulates the growth, rather than initiation, of the intestinal adenomas in the Apcmin/+ 
mice. 
TBK1 deficiency does not influence the proliferation of IECs or adenoma cells  
To examine whether TBK1 regulates the proliferation of normal IECs or 
adenoma cells, we performed in vivo cell proliferation assays based on 
bromodeoxyuridine (BrdU) incorporation.  Six-week old Apcmin/+ and Apcmin/+Tbk1IEC-
KO mice were injected with BrdU intraperitoneally, and BrdU incorporation was 
assessed by immunohistochemical assays using an anti-BrdU antibody. We did not 
observe obvious differences in BrdU incorporation in normal mucosa between the 
Apcmin/+Tbk1IEC-KO and Apcmin/+ mice (Figure 11D-E).  These animals also did not 
show significant differences in BrdU incorporation within their microadenomas 
(Figure 11F-G). In addition to BrdU incorporation, we examined the proliferative 
effects of the TBK1 deficiency by immunocytochemistry staining with Ki67, a 
commonly used indicator for cells in the state of proliferation. Immunohistochemical 
analyses did not reveal appreciable differences in the frequency of Ki67+ cells in 
either the normal tissue or larger adenomas between four month old Apcmin/+ and 
Apcmin/+Tbk1IEC-KO mice (Figure 12A-C).   
TBK1 deficiency likely promotes cell survival of intestinal microadenomas  
We examined the role of TBK1 in regulating apoptosis using a TUNEL assay 
that detects fragmented DNA in apoptotic cells. Analyses of the Apcmin/+ and 
Apcmin/+Tbk1IEC-KO intestinal tissues did not reveal major differences in the frequency 
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of TUNEL positive apoptotic cells in the normal mucosa (Figure 13A-B).  
Interestingly, analyses of TUNEL positive cells in microadenomas from 
Apcmin/+Tbk1IEC-KO intestinal tissues revealed a trend toward enhanced cell survival 
as compared to Apcmin/+ mice (Figure 13C-D). Because we did not achieve statistical 
significance with p = 0.07 (Figure 13D) using the arbitrary threshold of p < 0.05, we 
can not exclude the possibility that the observed difference may be due to chance.  
However, if we test with a less stringent threshold of 10 percent significance, then 
the difference of TUNEL positive cell frequency between the microadenomas in 
Apcmin/+ and Apcmin/+Tbk1IEC-KO may achieve statistical significance. Additionally, if 
we consider the 90 percent confidence intervals of 2.5 to 0.13 for these data, then it 
is likely that IEC-specific Tbk1 deletion promotes cell survival in microdadenomas in 
Apcmin/+ mice. Further analyses are needed to make more solid conclusions.  
Additional sections of microadenomas will be analyzed to increase the number of 
observations per group.  Furthermore, given that IEC-specific Tbk1 ablation 
promotes enlargement in medium-sized tumors, we will assess the apoptotic indexes 
of medium sized tumors from Apcmin/+ and Apcmin/+Tbk1IEC-KO. 
IEC-specific Tbk1 ablation does not cause visible intestinal inflammation 
Recent findings have revealed a complex relationship between inflammation 
and cancer, suggesting that the immune response can both suppress and promote 
tumor development16,88. More recently, intestinal chronic inflammatory diseases have 
been identified as a risk factor for colon cancer89,90.  Under normal conditions, the 
immune system does not mount strong responses to commensal microbes, which is 
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important for the maintenance of intestinal immune homeostasis and prevention of 
inflammation. Impaired barrier function or innate immune function in intestinal 
epithelia may cause bacterial invasion and chronic inflammation. Since TBK1 has 
been implicated in the regulation of innate immunity and inflammatory processes40,72, 
we examined whether Tbk1 ablation in IECs might impair immune homeostasis and 
cause intestinal inflammation. 
To determine if TBK1 in IECs plays a role in immune homeostasis in the gut, 
we sacrificed wildtype and Tbk1IEC-KO mice and resected the colons and small 
intestines to count the number of Peyer’s patches in the small intestine.  Both the 
small intestine and colons were formalin-fixed, cut and H&E stained.  We examined 
the colonic tissues and counted the number of colonic lymphoid follicles visible in 
two bi-level sections of swiss-rolled tissues.  We observed no significant difference 
in the number of Peyer’s patches nor colonic patches between Tbk1 wildtype and 
Tbk1IEC-KO mice (Figure 9A-B). With the assistance of a pathologist, we blindly 
scored the tissues based on the presence of immune cells within the mucosa, 
submucosa, and/or transmural and on the extent of the mucosal damage (Table 1).  
We observed no overt histological difference in inflammation between Tbk1 wildtype 
and Tbk1IEC-KO mice (Figure 9C-D).  These data suggest that IEC-specific Tbk1 
deletion alone in the IECs does not impair immune homeostasis nor lead to 
spontaneous inflammation in the gut.   
Intestinal tumorigenesis may be promoted by altered production of pro- 
versus anti-inflammatory cytokines without overt histological inflammation91. 
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Therefore, we tested whether the TBK1 deficiency caused low-grade inflammation 
within the intestine by analyzing gene expression of inflammatory mediators using 
real-time quantitative PCR (qPCR). We detected the expression of pro- and anti-
inflammatory cytokines, chemokines and cell markers such as Tnfα, Il1β, Il17a, Il17f, 
Il10, Il12p35, Ccl2, Cox2, Foxp3, Tgfβ, and interferons (IFNs) including Ifnα, β and γ 
by performing qPCR. These inflammatory mediators have previously been identified 
to play a role in tumor development. There was no detection of significant difference 
in any of these inflammatory proteins in Tbk1IEC-KO as compared to wildtype mice 
(Figure 14). Taken together, these data suggest that Tbk1 deletion alone in IECs 
does not appreciably alter inflammatory environment in the gut nor does it 
spontaneously induce polyp formation even after aging the mice for one year (Figure 
9D).  
Tbk1 ablation in IECs does not promote inflammation or adenoma formation in 
a chemically induced colitis-associated tumor model. 
Severe colitis can be induced by interrupting the epithelial barrier using 
chemicals, such as dextran sodium sulfate (DSS). The DSS-induced colitis has been 
frequently used for the study of inflammation and inflammation-associated cancer. 
DSS damages the colonic epithelial cell barrier thus inducing an immune response to 
the colonic microbes mediated by innate immune cells70. We treated Tbk1IEC-KO and 
wildtype mice with DDS for either five or seven days with two-day water recovery 
period (Figure 15A). The mice were weighed once per day during this treatment 
period and sacrificed at day two after DSS treatment. We observed no difference in 
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the weight or the histological score between wildtype and Tbk1IEC-KO.  Both groups of 
mice exhibited similar levels of decreased weight loss and colonic inflammation after 
treatment (Figure 15B-F).   
To test the role of IEC-specific TBK1 in colitis-associated colon cancer, we 
treated wildtype and Tbk1IEC-KO mice with a single dose of azoxymethane (AOM), a 
genotoxic colon carcinogen, and several cycles of DSS and water92 (Figure 16A).  
Consistent with the results obtained in mice treated with DSS alone, the IEC-specific 
TBK1 deficiency did not alter the level of inflammation in mice treated with DSS 
along with AOM, as shown by the similar level of bodyweight loss and colon 
shortening in the wildtype and Tbk1IEC-KO mice (Figure 16B and D). We also 
observed no difference in the number of polyps formed in the colons of wildtype and 
Tbk1IEC-KO mice (Figure 16C). Therefore, we hypothesize that TBK1 functions in 
IECs through another mechanism, possibly by modulating the adaptive immune cell 
component in the intestines. It is also possible that in our model, TBK1 in IECs may 
exert its functions in the context of Apc mutations.  
The effect of TBK1 deficiency on adenoma formation is diminished in the 
absence of lymphocytes  
To examine the role of adaptive immune system in regulating adenoma 
formation in Apcmin/+ and Apcmin/+Tbk1IEC-KO mice, we crossed these mice with Rag1 
knockout mice lacking mature T and B lymphocytes, key cellular mediators of the 
adaptive immune system93.   We crossed Apcmin/+ Tbk1 IEC mouse model with Rag1 
knockout mice. The small intestines of the mice were resected, fixed and counted for 
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number of polyps at age 2.5-3 months.  As expected, Apcmin/+Tbk1IEC-KO mice had a 
substantially higher number of polyps than Apcmin/+ Tbk1 mice under lymphocyte-
competent conditions (Figure 17). When crossed to the Rag1 knockout background, 
the number of polyps was greatly enhanced in both Apcmin/+Tbk1IEC-KO and Apcmin/+ 
mice (Figure 17), likely due to the loss of the immunosuppressive Treg cells and/or 
IELs38, 39. Moreover, under these lymphocyte-free conditions, the TBK1 deficiency 
only had a moderate, and statistically insignificant, effect on polyp formation.  
The results described above suggest that TBK1 may regulate an aspect of 
adaptive immune homeostasis that is masked by the loss of Treg and other 
lymphocytes in the Rag1 knockout conditions. We first examined the effect of TBK1 
on immune homeostasis by analyzing the intestinal immune cell composition, 
specifically lymphocytes in addition to innate immune cells. We resected the small 
intestines of young mice and isolated both intestinal IELs and the lamina propria 
cells94. The Apcmin/+Tbk1IEC-KO and Apcmin/+ mice had a comparable frequency of 
TCRβ+ or γδTCR+ T cells (Figure 18 A-B; Figure 19 A-B) and myeloid CD11c+ 
and/or CD11b+ cells (Figure 18 C-D) in either the lamina propria or IEL 
compartments of the small intestine. The expression levels of Foxp3, a marker for 
Treg cells, were also similar between Apcmin/+Tbk1IEC-KO and Apcmin/+ mice (Figure 
18E).  These results suggest that loss of TBK1 in IECs does not alter the immune 
cell composition in the intestinal tissue, raising the question of whether the TBK1 
deficiency may cause abnormal function of the intestinal lymphocytes. 
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TBK1 deficiency in the IECs of Apcmin/+ mice inhibits Il10 production in the 
intestine  
 Although IEC-specific Tbk1 deletion alone does not alter the expression of 
cytokines in the intestine (Figure 14), it remains possible that TBK1 plays a role in 
regulating cytokine protein in the context of Apc mutation. This possibility was 
suggested by the profound effect of TBK1 deficiency on adenoma formation in the 
Apcmin/+ mice. We therefore tested Apcmin/+ mice the effect of TBK1 deficiency in IECs 
on the expression of various cytokines and chemokines involved in the inflammatory 
process and cancer (Figure 20A). Because of the crucial role of TBK1 in regulating 
type I interferon induction, we also included interferon-responsive genes, such as 
Il10, Cxcl11, Cxcl9, Cxcl10, and Irf7, which have been shown to be effected by the 
loss of TBK1 in innate immune cells. In addition, we examined the β-catenin target 
genes Axin2 and Lgr5, to assess the possible role of IEC-specific TBK1 in regulating 
Wnt signaling pathway, as well as genes involved in host defense (Reg3β and 
muc2). We quantitatively analyzed the expression of these genes from intestinal 
tissues of young 3.5-4 week old Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice presumably 
before microscopic adenoma formation. Interestingly, the IEC-specific TBK1 
deficiency in Apcmin/+ mice significantly inhibited the gene expression of the anti-
inflammatory cytokine Il10 in the intestine, although the expression of the rest of the 
genes was comparable between the Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice (Figure 
20A). Il10 expression levels are sustained in mice after sole IEC-specific deletion of 
Tbk1 or sole Apcmin/+ genotype (Figure 20B). Given the crucial role for IL-10 in 
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suppressing intestinal tumorigenesis, this finding provides important insights into the 
mechanism by which TBK1 regulates adenoma formation in the Apcmin/+ mice.  
IEC-specific TBK1 regulates IL-10 production by IELs  
As mentioned in Chapter 2, IECs can secrete cytokines and chemokines to 
initiate a mucosal immune response upon detection of commensal and pathogenic 
antigens, guiding homeostasis within the environment14. While there is little evidence 
of IECs expression of Il10 in vivo, it has been shown that human IECs can produce 
this anti-inflammatory cytokine in vitro95,96.  In addition, IECs may stimulate IL-10 
production by macrophages and lymphocytes, but the underlying mechanism has 
not been defined97. A large source of IL-10 in the intestine is produced by the IELs, 
although some cell types of the lamina propria (e.g. macrophages, dendritic cells, 
and regulatory T cells) can also produce IL-1012,38.  In fact, intestinal IELs suppress 
chronic intestinal inflammation in an IL-10-dependent manner.39  Therefore, 
analyzed Il10 expression in highly purified IECs, intestinal epithelial lymphocytes, 
and lamina propria cells of the Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice. To our surprise, 
the IEC-specific Tbk1 knockout did not affect Il10 expression in the IECs but 
impaired the Il10 expression in IELs (Figure 21A-B). This effect was specific, since 
the TBK1 deficiency did not affect Il10 expression in the lamina propria cells (Figure 
21C). This finding supports the previous in vitro finding that IECs stimulate IL-10 
production in lymphocytes and establishes TBK1 as an important factor mediating 
this crosstalk in vivo.  
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Discussion 
The data presented in this study show that TBK1 functions in IECs to inhibit 
intestinal adenoma growth in Apcmin/+ mice.  Loss of TBK1 in IECs of Apcmin/+ mice 
resulted in increased polyp formation in the small intestines, a phenotype observed 
as early as six weeks of age. The increase in polyp number in the Apcmin/+Tbk1IEC-KO 
mice was seen in both the proximal and distal regions of small intestine, but this 
phenotype was more pronounced in the distal region. Polyp size was greater in the 
Apcmin/+Tbk1IEC-KO mice as compared to Apcmin/+ mice, specifically in the medium 
sized adenomas.   
 TBK1 has previously been shown to be important in regulating the immune 
response by mediating type I interferon production, IgA production, and T cell 
activation and migration48,59,98. In addition, previous in vitro studies using human lung 
and breast cancer cell lines implicate TBK1 to have tumor-promoting 
activity45,60,62,66,72. TBK1 knockdown promotes apoptosis and reduces xenograft 
tumor growth of KRAS-dependent lung cancer cells but not of KRAS-independent 
tumor cell lines60. TBK1 appears to also contribute to the resistance of breast cancer 
cells to tamoxifen resistance72. However, a more recent publication challenged some 
of these findings and suggest that some of the phenotypes of TBK1 knockdown 
cancer cell lines may be due to off-target effect of the TBK1 shRNAs73. In addition to 
the controversy, the previous work also had several limitations in addressing the 
cancer-regulatory function of TBK1. First, the use of mouse xenograft models, which 
rely on immunodeficient recipient mice, excludes the contribution of immune system, 
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a major component of the tumor microenvironment that regulates tumor growth and 
progression. Second, since human cell lines often have accumulated genetic 
alterations, the cell line studies cannot assess the role of TBK1 in regulating the 
early-stages of tumorigenesis. Furthermore, the use of shRNA-mediated knockdown 
approach or pharmacological inhibitors of TBK1 have the issue of specificity due to 
off-target effect shRNAs and pharmacological inhibitors. Our conditional Tbk1 KO 
mouse model allowed us to study the in vivo role of TBK1 during the early stages of 
intestinal tumorigenesis in immunocompetent mice. With our new approach, we 
discovered an unexpected function of TBK1 in suppressing the formation of intestinal 
adenoma, an early stage of CRC development. 
Within the mucosa, IELs, predominately CD8+ T cells, are interspersed 
throughout and in direct contact with the epithelial cell layer; this puts them along 
with the IECs at the forefront of the intestinal immune response. As part of the 
mucosa, the lamina propria, which lies beneath a basal membrane under the IEC 
and IEL layers, defines a compartment for heavily infused circulating immune cells 
particularly T lymphocytes including effector T cells and Treg cells, macrophages, 
plasma cells, eosinophils, and mast cells. The IECs can express immunological 
mediators to help guide the appropriate response to commensal microbes or 
pathogens, a delicate balance required to achieve homeostasis within the 
environment14. We found that TBK1 in IECs function to regulate Il10 expression in 
IELs to produce IL-10 during the early stages of the tumorigenic process, which is 
illustrated in a schematic in Figure 22. Previous studies showed that IL-10-deficient 
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mice developed enterocolitis in the duodenum, jejunum, and colon and that Il10 
knockout weanlings, the age where gastrointestinal normal flora begin colonization, 
exhibited early signs of focal inflammatory lesions in the intestine which progresses 
to transmural inflammation, epithelial hyperplasia and then adenocarcinoma with 
age34,36. Higher levels of proinflammatory cytokines such as TNF-α, IL-6, IL-1β and 
IFN-γ were present in the colons of IL-10-deficient mice as compared to wildtype 
control mice.  These sequelae were prevented in weanlings of Il10 knockout mice 
when treated with IL-10 intraperitoneally such that the incidence of adenocarcinoma 
in these mice was reduced36.  These early findings suggest that IL-10 is required for 
maintaining intestinal homeostatic conditions and its loss can lead to intestinal 
inflammatory disease and colorectal cancer. Impaired IL-10 production in the 
intestine is also linked to enhanced intestinal tumorigenesis in other knockout mouse 
models crossed with the Apcmin/+ mice91. Thus, our finding that TBK1 deficiency in 
IECs inhibits IL-10 production provides mechanistic insight into the role of TBK1 in 
regulating intestinal adenoma formation. 
We demonstrated that the tumor-regulating function of TBK1 is diminished 
when the Apcmin/+Tbk1IEC-KO mice were crossed to the lymphocyte-deficient Rag1 
knockout background. Under these conditions, the number of polyps was greatly 
increased in both the Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. Since Rag1 knockout 
mice lack both conventional T cells and Treg cells, it is likely that the lack of 
immunosuppressive Treg cells may contribute to an inflammatory environment that 
promotes tumor formation33-86. Indeed, transfer of wildtype Treg cells into the Apcmin/+ 
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mice reduces tumor burden24. More importantly, the tumor-suppressing function of 
Treg cells requires their production of the immunosuppressive cytokine IL-1024. Of 
note, intestinal IELs suppress intestinal inflammation in an IL-10-dependent 
manner39. Our finding that TBK1 regulates Il10 expression in the intestine thus has 
important implications. Although TBK1 does not seem to regulate Il10 expression in 
Treg cells, the IEC-specific TBK1 is required for IL-10 production by another major 
source of IL-10 producing cells, the IELs. Additional studies are required to elucidate 
the mechanism underlying this novel and intriguing function of TBK1. One 
hypothesis is that TBK1 may regulate the production of a secreted factor(s) in IECs, 
which in turn stimulate the IELs for IL-10 expression.  
Clinical Importance 
As previously mentioned in Chapter 2, the localization of human chromosome 
12q14.1, the region where TBK1 lies, is associated with chromosomal abnormalities 
in cancers including in pancreatic, ovarian, skin, breast, prostate, and salivary duct 
cancers and pulmonary chondroid hamartomas74-79. Of particular interest, shallow 
deletions and gains of TBK1 accounted for 20 percent and 30 percent of 
adenocarcinoma tissue samples sequenced from the large intestine of patients 
within validated and provisional (Figure 7) datasets of The Cancer Genomics Atlas 
(TCGA) respectively.  Publicly available through TCGA consortia using 
www.cbioportal.org, these datasets contain comprehensive large-scale genomic, 
transcriptomic and epigenomic profiling of various cancers including colorectal 
cancer 80,81. The copy numbers of TBK1 significantly correlated with TBK1 mRNA 
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expression in these samples (Figure 23A), where TBK1 mRNA expression 
significantly decreased or increased in samples with putative shallow deletions or 
gains as compared to diploid TBK1 copy-number respectively (Figure 23B). 
However, neither TBK1 copy number nor mRNA expression levels significantly 
correlated with the overall survival of these patients (Figure 24).  However, analysis 
of TBK1 mRNA expression levels within different stages of colorectal cancer, from 
stage I through stage IV, revealed a significant correlation between TBK1 mRNA 
expression in tumors sampled during stage IIIC and the overall survival of those 
patients (Figure 25 A-B). During stage IIIC of disease, the cancer has grown through 
the outer layers of the intestine into the visceral peritoneum and has spread to 
nearby lymph nodes but has not yet reached nearby tissues or distant organs99.  In 
addition, a moderately high correlation existed between TBK1 mRNA expression in 
tumors during early stage of disease to TBK1 mRNA expression in tumors during 
later stages (Figure 25 C), suggesting a strong relationship between the degree to 
which TBK1 is expressed in early staged tumors and in later stages as the cancer 
progresses.  
Further analyses using these profiles were performed to determine the clinical 
relevance for the role of TBK1 in colon cancer. Similar to the trends found with TBK1 
mRNA expression using TCGA data were trends found with expression of APC, 
TP53, KRAS, and PIK3CA genes (Figure 26), well-known regulators of the 
tumorigenic process17,30,87,100,101.  In fact, APC, TP53, KRAS, and PIK3CA are 
among the top five most frequently mutated genes, with a frequency of mutation at 
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61 percent, 43 percent, 34 percent, and 16 percent respectively in the validated 
dataset of TCGA (Figure 26A).  Although copy numbers of these genes - APC, 
TP53, KRAS, and PIK3CA - significantly correlated with its respective mRNA 
expression (Figure 26B) as did TBK1 copy number and its mRNA expression (Figure 
23A), no correlations were found between the copy number (Figure 27A) or mRNA 
expression levels (Figure 27B) of either gene and the overall survival of the patients 
as observed with TBK1 and overall survival irrespective of disease stage (Figure 
24).  This suggest that the correlation between patient overall survival and gene 
expression of recurrently mutated genes may not be sufficient to predict its role in 
cancer development.  
As an important signal transducer in various downstream biological 
processes, TBK1 function is dependent upon its molecular structure as well as its 
expression pattern40.  Interestingly, point mutations in TBK1 were found in 
approximately two percent of the large intestinal genomic profiles from 1,226 patient 
tumor samples deposited in Catalogue of Somatic Mutations in Cancer 
(COSMIC)82,83.  Twenty-two different TBK1 mutations (Table 2) in these patient 
samples included missense, nonsense and synonymous substitutions as well as 
frame-shift deletion and insertion, and in-frame deletion and were relatively 
dispersed throughout the KD, ULD, SDD and CTD of TBK1 with missense mutations 
accounting for the majority (Table 2; Figure 3; Figure 28). Mutationassessor.org 
software offered by cBio@MSKCC uses evolutionary conservation patterns of intra- 
and interspecies homologues in families and sub-families empirically to predict the 
impact of amino acid substitutions on protein function. With this software, functional 
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impact scores are calculated using multiple sequence alignments, with the 
assumption that protein function is likely affected by specific substitutions of 
conserved residues102.  To predict the functional impact of the missense TBK1 
mutations listed in Table 2, each mutation was assessed using the algorithm 
provided. Only two of the 14 missense mutations were classified as a “medium” level 
of functional impact, predicting that these mutations may alter the function of TBK1 
(Table 2).   Both of these mutations, F56C and A188V, were localized within the 
catalytic and activation loops of the KD of TBK1 respectively.  A change in 
conserved residues within these loops could potentially alter the function of TBK1 
since the structural configuration of these loops within the KD influence the activation 
state of TBK141.  Experimental validation is needed to test this prediction. 
Almost half of missense mutations found in TBK1 were given a “low” score for 
functional impact, predicting that these specific mutations would have no influence 
on TBK1 function (Table 2).  These mutations were primarily localized within the 
ULD and SDD of TBK1.  Each domain of TBK1 influences its context-specific 
function41-43,84.  Particularly, the ULD of TBK1 interacts with its own KD and SDD and 
is required for the full activity of TBK1 KD; this is critical for the regulation of IFN-
inducible gene transcription during an immune response42,84. Furthermore, the ULD 
and KD of TBK1 interact with the SDD of the other TBK1 subunit in the dimer, while 
the CTD serves as a binding site for several adaptor proteins involved in TBK1-
mediated signal transduction41-43,103.  These intricacies in the structure of TBK1 
become particularly important as we determine the functional implications for TBK1 
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sequence alterations revealed in the TCGA and COSMIC databases. For example, 
mutationassessor.org predicted that E355K substitution would not influence the 
function of TBK1 (Table 2).  However, E355 is a key residue at the ULD interface 
that participates in TBK1 homodimerization. TBK1 E355A, R357D, and 
E355A/R357D double mutations disrupted the activation of TBK1 and downstream 
signaling events, which diminished TLR-induced type I interferon gene expression in 
vitro 43.  These findings support the need for experimental validation of all predicted 
outcomes of amino acid substitutions determined by mutationassessor.org, including 
TBK1 E355K.  While mutationassessor.org is limited to predicting the effect of 
missense mutations, one could predict that nonsense mutations such as TBK1 
R357* found in the COSMIC database (Table 2) may alter the activity of TBK1 given 
that R357D mutation impaired its function and truncation within the ULD would likely 
alter TBK1 homodimerization, activation and substrate specificity 41-43,84.  
The molecular structure, the subcellular localization, the specificity of binding 
partners and substrates, and the expression pattern directs the activity of TBK1 in 
various cellular processes40. Further analyses of colorectal cancer patient profiles 
from TCGA using www.cbioportal.org indicated a strong relationship between the 
expression of TBK1 and other well-known factors involved in colorectal cancer 
initiation and progression, including APC, KRAS, and PIK3CA (Figure 29). TBK1 
mRNA expression highly and significantly correlated with the APC, KRAS and 
PIK3CA mRNA expression - three of the top five genes most frequently mutated in 
colorectal cancer patient samples (Figure 26A). Our in vivo model presented earlier 
  70 
in this chapter revealed that TBK1 functions in IECs to inhibit intestinal adenoma 
growth in Apcmin/+ mice (Figure 10), a model of early staged disease19. Our Tbk1 IEC 
conditional knockout model provides a mechanism that explains the strong positive 
association between TBK1 and APC gene expression gleaned from the 
transcriptomic profiles from TCGA (Figure 29).  A significantly strong positive 
association also existed between TBK1 and KRAS and TBK1 and PIK3CA gene 
expression.  The question still remains whether TBK1 negatively regulates intestinal 
adenoma growth in KRAS or PIK3CA mutant backgrounds.  Furthermore, TCGA 
patient sample data revealed a positive correlation between the mRNA expression of 
TBK1 and IL10 (Figure 30), which is consistent with the results of our in vivo model 
where IEC-specific deletion of Tbk1 diminished Il10 expression in the intestine. 
Taken together, these data support the clinical relevance of our model, providing a 
mechanism for the link between APC, TBK1 and IL-10 during intestinal adenoma 
development. 
The findings presented in this chapter illustrate the role of TBK1 during early 
stage develop of intestinal adenomas.  Because TBK1 currently serves as an 
attractive target in the discovery of anti-inflammatory and anti-cancer therapeutics 
where its pharmacological inhibitors are now readily available, the findings of the 
present study could have significant impact in the field. It suggests the need for 
careful consideration regarding the context in which TBK1 functions, which would 
ultimately aide in the selection of treatment modalities and preventative strategies for 
patients and influence the outcomes of treatments used to target this protein kinase. 
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My project studies suggest a need for careful consideration in the selection of 
treatment modalities targeting TBK1 in cancer patients of other tissue types as it is 
possible that long term use of TBK1 inhibitor could possible increase the risk for 
adenoma growth in the intestine. 
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Figure 8.  Generation of intestinal epithelial cell conditional Tbk1 mouse 
model. 
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Figure 8.  Generation of intestinal epithelial cell conditional Tbk1 and Apcmin/+ 
Tbk1 mice. Conventional Tbk1 KO mice are embryonic lethal56; therefore, to 
address our hypothesis, we generated Tbk1 intestinal epithelial cell-conditional KO 
(Tbk1IEC-KO) mice by crossing Tbk1 floxed mice with villin-Cre mice. A) Schematic 
image of Tbk1 gene targeting in IECs.  Two loxP sites were inserted adjacent to 
coding exon. Deleted allele depicts the removal of exon 2 after villin-Cre-mediated 
loxP recombination. B) PCR was used to detect the Tbk1 floxed and wildtype alleles 
and cre transgene in tail DNA. The +/+ Cre+ are indicated as Tbk1 wildtype while fl/fl 
Cre+ are indicated as Tbk1IEC-KO. C) Western blot was used to detect TBK1 protein 
levels from isolated primary IECs of the mice. D) IEC-conditional Tbk1 mice were 
crossed with Apcmin/+ mice to generate well-known Apcmin/+ colon cancer model.  
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Figure 9. Tbk1IEC-KO mice have normal development and intestinal 
homeostasis. IEC-specific ablation of Tbk1 does not induce spontaneous 
tumor formation as mice age.  
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Figure 9. Tbk1IEC-KO mice have normal development and intestinal 
homeostasis. IEC-specific ablation of Tbk1 does not induce spontaneous 
tumor formation as  mice age. After sacrificing 13 week old mice, small intestines 
and colons were resected.  A) Peyer’s patches in the small intestine were identified 
grossly and counted. Data presented as the mean ± SD. (n=2 wildtype; n=4 Tbk1IEC-
KO) B) Colonic patches were identified histologically and counted. Data presented as 
the mean ± SD. (n=2 wildtype; n=4 Tbk1IEC-KO) C) Small intestines were formalin-
fixed and histologically scored (based on inflammation extent and mucosal damage 
in Table 1) to determine alterations in tissue morphology. Data presented as the 
mean ± SD. (n=2 wildtype; n=4 Tbk1IEC-KO) D) Representative image of H&E stained 
tissue section of wildtype and Tbk1IEC-KO small intestines at one year of age. (n=3 
wildtype; n=4 Tbk1IEC-KO) 
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Figure 10. IEC-specific TBK1 ablation greatly promotes adenoma development 
in Apcmin/+ mice.  
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Figure 10.  IEC-specific TBK1 ablation greatly promotes adenoma formation in 
Apcmin/+ mice.  A) Representative images of tumor development in the small 
intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age.  B) Polyp 
numbers in the entire small intestine, distal region (13cm from the caecum) and 
proximal regions. C) Summary of tumor sizes in the entire small intestine. D) H&E 
staining of the distal region of the small intestine showing increased adenomas in 
Tbk1IEC-KO mice at four months of age. E) Representative picture of large multifocal 
adenomas in the distal region of the small intestine from the Apcmin/+Tbk1IEC-KO mice 
at six months of age. Each symbol in the graphs represents an individual mouse. 
The data are presented as mean ± SEM.  The symbol * represents p < 0.05 and ** 
represents p < 0.01.  
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Figure 11. TBK1 deficiency in IECs promotes polyp formation in young mice 
Apcmin/+ mice. 
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Figure 11. Young Apcmin/+Tbk1IEC-KO mice exhibit earlier polyp formation as 
compared to Apcmin/+ mice. A) Polyp (gross macroadenoma) numbers in the entire 
small intestine at six weeks of age. B) Microadenoma numbers in the entire small 
intestine histologically-identified (tri-level) at six weeks of age. C) Representative 
images of histologically-identified microadenomas of the small intestines of Apcmin/+ 
and Apcmin/+Tbk1IEC-KO mice at six weeks of age. D) Representative images of BrdU 
immunohistochemical staining of the normal mucosa in the small intestines of 
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. E) Enumeration of the of 
BrdU+ cells per crypt within the normal mucosa of the small intestines of Apcmin/+ and 
Apcmin/+Tbk1IEC-KO mice at six weeks of age. F) Percentage of BrdU positive (+) cells 
per microadenoma determined as the percentage of BrdU+ nuclei per DAPI stained 
nuclei per microadenoma.  All microadenomas identified per swiss-rolled intestinal 
tissue section were analyzed.  The data are presented as mean ± SEM values (n= 5 
Apcmin/+ mice; n=7 Apcmin/+Tbk1IEC-KO mice.  Each symbol in the graphs represents an 
individual mouse.  The symbol * represents p < 0.05. 
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Figure 12. IEC-specific TBK1 ablation does not influence the proliferation of 
IECs or adenoma cells in older Apcmin/+ mice. 
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Figure 12. IEC-specific TBK1 ablation does not influence the proliferation of 
IECs or adenoma cells in older Apcmin/+ mice.  A) Representative images of Ki67 
immunohistochemical staining of the normal mucosa of the small intestines of 
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age. B) Representative 
images of Ki67 immunohistochemical staining of the adenomas in the small 
intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age. C) 
Enumeration of the percentage of Ki67 + cells per field of view for the large 
adenomas in the small intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four 
months of age.  
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Figure 13. IEC-specfic-TBK1 deficiency promotes cell survival in the intestinal 
microadenomas of Apcmin/+ mice. 
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Figure 13. IEC-specfic-TBK1 deficiency likely promotes cell survival in the 
intestinal microadenomas of Apcmin/+ mice. A) Representative images of TUNEL 
fluorescent and DAPI staining of the normal mucosa of the small intestines of 
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. B) Percentage of TUNEL 
positive (+) cells per villus determined as the percentage of GFP positive nuclei per 
DAPI positive nuclei per villus. Graph presents mean ± SEM values (n=3 mice per 
genotype; at least 6-9 images of different intestinal tissue focal areas were analyzed 
per mouse counting cells of at least 6-7 villi per area). C) Representative images of 
TUNEL fluorescent and DAPI staining of microadenomas of the small intestines of 
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. D) Percentage of TUNEL 
positive cells per microadenoma determined as the percentage of GFP positive 
nuclei per DAPI positive nuclei per microadenoma. Graph presents mean ± SEM 
values (n= 6 Apcmin/+ mice; n=5 Apcmin/+Tbk1IEC-KO mice; p=0.071; 90% CI = 2.45, 
0.135). Each symbol in the graph represents mean percentage of an individual 
mouse. All microadenomas identified per swiss-rolled intestinal tissue section were 
analyzed.  
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Table 1. Histological colitis and small intestinal inflammation scoring method.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1!
A.  Histological Colitis Scoring Method (modified from K. Williams et. Al, Gastroenterology (2001))!
Feature scored ! ! ! !    Score ! !Description !!
Inflammation extent! ! ! ! !0 ! !none !!
! ! ! ! !1 ! !mucosa!
! ! ! ! !2 ! !mucosa and submucosa!
! ! ! ! ! ! !3 ! !transmural!
Mucosal damage ! ! ! ! !0 ! !none !!
! ! ! ! ! ! !0 ! !intraepithelial neutrophils and crypt abscess!
! ! ! ! ! ! !1 ! !crypts lost; surface epithelium present!
                                                    ! ! !2         !focal ulcers present (cypts and surface epithelium lost)!
! ! ! ! ! ! !3 ! !diffuse/extensive ulcer!
 !
B.  Small intestine histological scoring method (Modified from Gomes-Santos et. al; Clinical and Developmental Immunology (2012) !
Feature scored ! ! ! !      Score ! !Description!
extent of damage to mucosal architecture !0 ! !normal !
1 ! !mild !
2 ! !moderate!
3 ! !extensive !
degree of cellular infiltration ! ! !0 ! !normal !
1 ! !mild !
2 ! !moderate!
3 ! !transmural!
extent of muscle thickening ! ! !0 ! !normal !
1 ! !mild !
2 ! !moderate!
3 ! !extensive !
crypt abscesses ! ! ! ! !0 ! !absent !
1 ! !present!
loss of goblet cells ! ! ! ! !0 ! !absent !
1 ! !present!
Supplemental Figure.  !
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Table 1. Histological colitis and small intestinal inflammation scoring method.  
Tissue sections from either the colon or the small intestine of Tbk1IEC-KO and wildtype 
mice were H&E stained and blindly scored based on the presence of immune cells 
within the mucosa, submucosa, and/or transmural and on the extent of the mucosal 
damage. 
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Figure 14.  Tbk1 deletion in IECs does not alter the expression of 
inflammatory mediators in the gut.  
 
 
 
 
IL-10 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
KO
0
1
2
3
WT
TBK1 IEC-KO
Tbk1+/+! Tbk1 IEC-KO!
IL12p35 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
KO
0.0
0.5
1.0
1.5
WT
TBK1 IEC-KO
TGFbeta 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
KO
0.0
0.5
1.0
1.5
WT
TBK1 IEC-KO
Tbk1+/+! Tbk1 IEC-KO!Tbk1+/+! Tbk1 IEC-KO! Tbk1+/+! Tbk1 IEC-KO!
IFN beta
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0
2
4
6
8
WT
TBK1 IEC-cKO
IFN alpha
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0
5
10
15
WT
TBK1 IEC-cKO
IFN gamma
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0
1
2
3
4
WT
TBK1 IEC-cKO
Foxp3 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0.0
0.5
1.0
1.5
2.0
WT
TBK1 IEC-cKO
IL-17A
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0.0
0.5
1.0
1.5
WT
TBK1 IEC-cKO
TNF-alpha
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0.0
0.5
1.0
1.5
2.0
2.5
WT
TBK1 IEC-cKO
IL-1 beta
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0
2
4
6
WT
TBK1 IEC-cKO
IL-17F 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0
2
4
6
8
WT
TBK1 IEC-cKO
CCL2
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
WT
TB
K1
 IE
C-
cK
O
0.0
0.5
1.0
1.5
2.0
2.5
WT
TBK1 IEC-cKO
Tbk1+/+! Tbk1 IEC-KO! Tbk1+/+! Tbk1 IEC-KO!Tbk1+/+! Tbk1 IEC-KO! Tbk1+/+! Tbk1 IEC-KO!
Tbk1+/+! Tbk1 IEC-KO! Tbk1+/+! Tbk1 IEC-KO!Tbk1+/+! Tbk1 IEC-KO! Tbk1+/+! Tbk1 IEC-KO!
  87 
Figure 14.  Tbk1 deletion in IECs does not alter the expression of 
inflammatory mediators in the gut. qPCR analysis of indicated genes using the 
distal small intestines (13cm from caecum) wildtype or Tbk1IEC-KO mice. Normalized 
expression levels were calculated relative to the expression of internal control Actb. 
Data are presented as mean ± SEM based on multiple samples and representative 
of one experiment. Each symbol represents a mouse.  
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Figure 15. Tbk1 ablation in IECs does not promote inflammation in a 
chemically induced colitis model. 
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Figure 15. Tbk1 ablation in IECs does not promote inflammation in a 
chemically induced colitis model.  A) Schematic of treatment with DSS for five or 
seven days followed by two-day recovery with water before sacrificing Tbk1IEC-KO 
and wildtype mice. B) Tbk1IEC-KO and wildtype mice were weighed each day during 
3.5% DSS treatment for seven days followed by two day recovery with water.  Data 
presented as mean change in weight ± SD as percentage (n=5 per genotype).  C) 
After treatment and recovery, colons were resected, formalin-fixed, H&E stained and 
histologically scored for evidence of inflammation (based on inflammation extent and 
mucosal damage in Table 1). Data presented as the mean ± SD (n=5 each group). 
D) Representative H&E stained colonic tissue section from mice treated with 3.5% 
DSS for seven days. The extent of tissue damage in both groups was similar in 
tissue sections from mice treated with 3% DSS (data not shown).  E) Tbk1IEC-KO and 
wildtype mice were weighed each day during 3.0% DSS treatment for five days 
followed by two day recovery with water.  Data presented as mean change in weight 
± SD as percentage (n=5 per genotype). 
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Figure 16. Tbk1 ablation in IECs does not promote inflammation or adenoma 
formation a chemically induced colitis-associated tumor model.  
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Figure 16. Tbk1 ablation in IECs does not promote inflammation or adenoma 
formation a chemically induced colitis-associated tumor model.  A) Schematic 
of treatment with a single dose of azoxymethane (AOM) followed by three cycles of 
DSS and water before sacrificing Tbk1IEC-KO and wildtype mice. B) Tbk1IEC-KO and 
wildtype mice were weighed as indicated during treatment.  Data presented as mean 
± SD (n=9 wildtype; n=7 Tbk1IEC-KO).  C) After three cycles of DSS/water treatments, 
colons were resected and measured for length. Data presented as mean ± SEM. D) 
Colons were formalin-fixed and number size of gross polyps was determined. Data 
presented as mean ± SEM. Each symbol in the graphs (C and D) represents an 
individual mouse. 
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Figure 17. The effect of TBK1 deficiency on adenoma formation is diminished 
in the absence of lymphocytes. 
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Figure 17. The effect of TBK1 deficiency on adenoma formation is diminished 
in the absence of lymphocytes.  Gross adenomas in the entire small intestine 2.5 
to 3 months old Apcmin/+ Rag1 knockout and Apcmin/+Tbk1IEC-KO Rag1 knockout mice 
were counted. The data are presented as mean ± SD (n=3 for Apcmin/+ Rag1 
knockout mice and n=2 for Apcmin/+Tbk1IEC-KO Rag1 knockout mice). 
  
  94 
Figure 18. IEC-specific Tbk1 ablation in Apcmin/+ mice does not alter the 
frequency of immune cell composition in intestinal lamina propria.  
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Figure 18. IEC-specific Tbk1 ablation in Apcmin/+ mice does not alter the 
frequency of immune cell composition in intestinal lamina propria. A) Flow 
cytometric analysis of CD45+ subpopulations of αβ T cells (TCRβ+) or γδ T cells 
(TCRγδ+) from the lamina propria of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice distal small 
intestines at three and one-half to four weeks old. Data are presented as a 
representative dot plot with each quadrant indicating the percentage of cells among 
total CD45+ cells. B) Summary graphs of mean ± SEM of lamina propria 
subpopulations of ab T cells and gd T cells based on two independent experiments. 
Each symbol represents a mouse.  Data represent two independent experiments. C) 
Flow cytometric analysis of CD45+ myeloid populations of CD11chi/int/- and/or 
CD11bhi/int/- cells from the lamina propria of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice distal 
small intestines at three and one-half to four weeks old. Data are presented as a 
representative dot plot with each quadrant indicating the percentage of cells among 
total CD45+ cells. D) Summary graphs of mean ± SEM of lamina propria 
subpopulations of CD11chi/int/- and/or CD11bhi/int/- myeloid cells based on two 
independent experiments. Each symbol represents a mouse.  Data represent two 
independent experiments. E) Distal small intestinal (SI) tissues were analyzed for 
Foxp3 mRNA expression using qPCR. Normalized expression levels were calculated 
relative to the expression of internal control Actb. Data are presented as mean ± 
SEM based on multiple samples and representative of one experiment. Each symbol 
represents a mouse.   
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Figure 19. Tbk1 ablation in IECs of Apcmin/+ mice does not alter the frequency 
of IEL subpopulations of αβ or γδ  T cells in the small intestine. 
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Figure 19. Tbk1 ablation in IECs of Apcmin/+ mice does not alter the frequency 
of IEL subpopulations of αβ or γδ T cells in the small intestine. Flow cytometric 
analysis of CD45+ IEL subpopulations of αβ T cells (TCRβ+) or γδ T cells (TCRγδ+) 
from the small intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at three and one-half 
to four weeks old. A) Data are presented as a representative dot plot with each 
quadrant indicating the percentage of cells among total CD45+ cells. B) Summary 
graphs of mean ± SEM of IEL subpopulations of ab T cells and gd T cells based on 
two independent experiments. Each symbol represents a mouse.  Data represent 
two independent experiments. 
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Figure 20. TBK1 deficiency in IECs leads to defective IL10 expression in 
Apcmin/+ mice small intestines. 
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Figure 20. TBK1 deficiency in IECs leads to defective IL10 expression in the 
intestines of Apcmin/+ mice. qPCR analysis of indicated genes using the distal small 
intestines (13cm from caecum) from A) Apcmin/+ and Apcmin/+Tbk1IEC-KO mice or B) 
wildtype, Tbk1IEC-KO, Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. Normalized expression 
levels were calculated relative to the expression of internal control Actb. Data are 
presented as mean ± SEM based on multiple samples and are representative 
graphs of two independent experiments. Each symbol represents a mouse. The 
symbol * represents p < 0.05. 
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Figure 21.   Loss of TBK1 in IECs results in diminished levels of IL10 
expression by intestinal IELs Apcmin/+ mice. 
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Figure 21.   Loss of TBK1 in IECs results in diminished levels of IL10 
expression by intestinal IELs Apcmin/+ mice. qPCR analysis of IL10 mRNA 
expression using A) primary IECs, B) primary IELs, or C) primary immune cells from 
the lamina propria (LP) of distal the small intestines from Apcmin/+ and 
Apcmin/+Tbk1IEC-KO mice. Normalized expression levels were calculated relative to the 
expression of internal control Actb. Data are presented as mean ± SEM based on 
multiple samples and are representative graphs of two independent experiments. 
Each symbol represents a mouse. The symbol * represents p < 0.05. 
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Figure 22. A schematic representing our proposed model of IEC-specific TBK1 
regulation of intestinal adenoma growth in vivo. 
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Figure 22. A schematic representing our proposed model of IEC-specific TBK1 
regulation of intestinal adenoma growth in vivo. A) Under normal conditions, 
intestinal homeostasis is maintained with IECs forming a single-layer barrier 
between the lumen and lamina propria.  Abnormal loss-of-heterozygosity (LOH) of 
tumor suppressor APC triggers deregulated cellular signaling and inflammation 
leading to microadenoma formation. TBK1 in IECs negatively regulates 
microadenoma to macroadenoma growth by maintaining the levels of 
immunosuppressive cytokine IL-10 produced by intestinal IELs during the 
tumorigenic process, resulting in apoptosis of adenoma cells. B) However, upon 
initiation of the adenoma formation in the absence of TBK1 in IECs, intestinal IELs 
express diminished levels of Il10. With continued aberrant cell signaling and 
inflammation after LOH of Apc, the absence of TBK1 in IECs promotes intestinal 
adenoma growth through increased adenoma cell survival. 
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Figure 23.  Copy numbers of TBK1 significantly correlated with TBK1 mRNA 
expression in colorectal adenocarcinoma samples deposited in TCGA. 
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Figure 23.  Copy numbers of TBK1 significantly correlated with TBK1 mRNA 
expression in colorectal adenocarcinoma samples deposited in TCGA. 
Copy number and mRNA expression data were collected using the RNASeqV2 data 
from validated (n=227) and provisional (n=375) genomic and transcriptomic profiles 
of colorectal adenocarcinoma tumor samples in TCGA at www.cbioportal.org74. (A) 
The correlation between copy numbers of TBK1 and TBK1 mRNA expression in 
colorectal adenocarcinoma samples deposited in TCGA. (B) TBK1 mRNA 
expression in samples with putative shallow deletions, diploid, gains or amplification 
with n for each group as indicated on graph. One-way ANOVA with Tukey’s multiple 
comparisons test was used to analyze mean differences in mRNA expression levels 
between groups of putative copy-number alternations with the exception of the 
putative amplification group (n=1).  Data presented as mean ± 95% confidence 
intervals with alpha of 0.05.   p-values of <0.05, <0.01, <0.001, <0.0001 correspond 
with (*), (**), (***), and  (***) annotations respectively. 
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Figure 24.  TBK1 copy number or mRNA expression in colorectal 
adenocarcinoma samples deposited in TCGA did not correlate with overall 
survival of patients. 
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Figure 24.  TBK1 copy number or mRNA expression in colorectal 
adenocarcinoma samples deposited in TCGA did not correlate with overall 
survival of patients. 
Overall patient survival data, TBK1 copy number, and TBK1 mRNA expression data 
were collected using the RNASeqV2 data from validated (n=227) and provisional 
(n=375) genetic profiles of colorectal adenocarcinoma tumor samples in TCGA at 
www.cbioportal.org74. (A) The correlation between copy numbers of TBK1 in 
colorectal adenocarcinoma samples in TCGA and overall survival (months) of 
patients. (B) The correlation between copy numbers of TBK1 mRNA expression in 
colorectal adenocarcinoma samples and overall survival (months) of patients.   The 
Pearson correlation test was used to examine correlation using data from the TCGA 
validated and provisional datasets. p-values of <0.05, <0.01, <0.001, <0.0001 
correspond with (*), (**), (***), and  (***) annotations respectively. 
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Figure 25.  TBK1 mRNA expression in colorectal adenocarcinoma samples 
from disease stage IIIC correlate with survival of patients; correlation exists 
between levels of TBK1 mRNA expression in samples from early and late 
stage of disease. 
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Figure 25.  TBK1 mRNA expression levels in colorectal adenocarcinoma 
samples from disease stage IIIC correlate with survival of patients; correlation 
exists between levels of TBK1 mRNA expression in samples from early and 
late stage of disease.  
Overall patient survival data and TBK1 mRNA expression data were collected using 
the RNASeqV2 data from validated and/or provisional) genetic profiles of colorectal 
adenocarcinoma tumor samples in TCGA at www.cbioportal.org74. (A) The 
correlation between mRNA expression of TBK1 in colorectal adenocarcinoma 
samples in TCGA during each disease stage from validated dataset (n=241) and 
overall survival (months) of those patients. The Pearson correlation test was used to 
examine correlation with n for each stage as indicated on graph. (B) The correlation 
between mRNA expression of TBK1 in colorectal adenocarcinoma samples in TCGA 
during each disease stage from provisional dataset (n=347) and overall survival 
(months) of those patients. The Pearson correlation test was used to examine 
correlation with n for each stage as indicated on graph. (C) Box and whisker plot of 
TBK1 mRNA expression in samples from disease stage I through stage IV from 
validated dataset (top) (n=241) and provisional dataset (n=347) (bottom).  The 
Pearson correlation test was used to examine correlation between stages of 
disease.  p-values of <0.05, <0.01, <0.001, <0.0001 correspond with (*), (**), (***), 
and  (***) annotations respectively. 
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Figure 26. APC, TP53, KRAS, and PIK3CA are among the top five most 
frequently mutated genes in colorectal adenocarcinomas. APC, TP53, KRAS, 
and PIK3CA mRNA expression correlates with copy number of its respective 
gene. 
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Figure 26.  APC, TP53, KRAS, and PIK3CA are among the top five most 
frequently mutated genes in colorectal adenocarcinomas. APC, TP53, KRAS, 
and PIK3CA mRNA expression correlates with copy number of its respective 
gene. (A) Frequency of mutation in APC, TP53, KRAS, SYNE1 and PIK3CA in the 
colorectal adenocarcinoma validated dataset of TCGA.  (B) Correlation between 
copy numbers of APC, TP53, KRAS, SYNE1 and PIK3CA and its respective mRNA 
expression in the colorectal adenocarcinoma validated dataset (n=227) of TCGA . 
mRNA expression data were collected using the RNASeqV2 data, frequency of 
mutation, and copy number are data from validated and/or provisional genetic 
profiles of colorectal adenocarcinoma tumor samples in TCGA. 
www.cbioportal.org74.  The Pearson correlation test was used to examine correlation 
between stages of disease.  p-values of <0.05, <0.01, <0.001, <0.0001 correspond 
with (*), (**), (***), and  (***) annotations respectively. 
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Figure 27.  No correlation between overall survival of patients and APC, TP53, 
KRAS, SYNE1 and PIK3CA copy number or mRNA expression in colorectal 
adenocarcinoma samples from validated TCGA dataset. 
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Figure 27. No correlation between overall survival of patients and APC, TP53, 
KRAS, SYNE1 and PIK3CA copy number or mRNA expression in colorectal 
adenocarcinoma samples from validated TCGA dataset.   
(A) Correlation between APC, TP53, KRAS, SYNE1 and PIK3CA copy number in 
colorectal adenocarcinoma samples from validated TCGA dataset (n=255) and 
overall survival (months) of patients. (B) Correlation between mRNA expression of 
APC, TP53, KRAS, SYNE1 and PIK3CA in colorectal adenocarcinoma samples from 
validated TCGA dataset (n=242) and overall survival of patients (months). mRNA 
expression data were collected using the RNASeqV2 data, copy number and overall 
survival are data from validated genetic profiles of colorectal adenocarcinoma tumor 
samples in TCGA. www.cbioportal.org74.  The Pearson correlation test was used to 
examine correlation between stages of disease.  p-values of <0.05, <0.01, <0.001, 
<0.0001 correspond with (*), (**), (***), and  (***) annotations respectively. 
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Figure 28.  Percentages of different types of TBK1 mutations found in the 
large intestine of patient colorectal adenocarcinoma samples (COSMIC and 
TCGA database). 
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Figure 28.  Percentages of different types of TBK1 point mutations found in 
the large intestine of patient colorectal adenocarcinoma samples (COSMIC 
and TCGA database). 
Pie chart indicating the percentages of different types of point mutations identified in 
CRC patient tumor samples (excludes cultured cell line data) sequenced from 
adenocarcinoma tissues of the large intestine deposited in Catalogue of Somatic 
Mutations in Cancer (COSMIC) and The Cancer Genome Atlas (TCGA) including 
missense, nonsense, and synonomous mutations as well as insertion and deletion 
frame-shifts deletion in-frame-shift.  Total of 22 mutations were found in these 
databases. 
  
  118 
Table 2.  Description and location of the point mutations found in the large 
intestine of patient tumor samples (COSMIC and TCGA database) with 
predicted functional impact determined by mutationassessor.org. 
 
  
Point mutation! Tissue site! Type!
Functional !
impact level!
Functional !
impact score! Database! Region of mutation!
TBK1 F56C! Colon! Missense! Medium! 2.785!
TCGA - 
validated!
Protein kinase domain !
(p. 9 -  307)!
TBK1 S347Y! Colon! Missense! Low! 1.245!
TCGA - 
validated!
Ubiquitin-like domain !
(p. 309 - 384)!
TBK1 S632L! Colon! Missense! Neutral! 0.55!
TCGA - 
validated!
Potential coiled domain !
(p. 626 - 713); !
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 T389I! Colon! Missense! Neutral! 0.46!
TCGA - 
validated!
Near ubiquitin-like domain !
(p. 309 - 384)!
TBK1 R357*! Colon! Nonsense! N/A! N/A!
TCGA - 
validated!
Ubiquitin-like domain !
(p. 309 - 384)!
TBK1 A188V! Colon! Missense! Medium! 2.41! COSMIC!
Protein kinase domain !
(p. 9 -  307)!
TBK1 A535T! Colon! Missense! Neutral! -0.805! COSMIC!
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 D720Y! Colon! Missense! Low! 0.805! COSMIC!
C-terminal domain!
 (p. 658 - 745)!
TBK1 E355K! Colon! Missense! Low! 1.1! COSMIC!
Ubiquitin-like domain !
(p. 309 - 384)!
TBK1 L366L! Rectum! Synonymous! N/A! N/A! COSMIC!
Ubiquitin-like domain !
(p. 309 - 384)!
TBK1 L366V!
Large 
intestine! Missense! Low! 0.805! COSMIC!
Ubiquitin-like domain!
 (p. 309 - 384)!
TBK1 M263V! Colon! Missense! Neutral! -0.025! COSMIC!
Protein kinase domain !
(p. 9 -  307)!
TBK1 Q289R! Colon! Missense! Low! 1.22! COSMIC!
Protein kinase domain !
(p. 9 -  307)!
TBK1 R574G! Colon! Missense! Low! 0.975! COSMIC!
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 R724C! Colon! Missense! Neutral! 0! COSMIC!
C-terminal domain !
(p. 658 - 745)!
TBK1 T599T! Caecum! Synonymous! N/A! N/A! COSMIC!
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 T651T! Colon! Synonymous! N/A! N/A! COSMIC!
Potential coiled domain !
(p. 626 - 713); !
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 V275D! Colon! Missense! Neutral! -2.66! COSMIC!
Protein kinase domain !
(p. 9 -  307)!
TBK1 R440*! Colon! Nonsense! N/A! N/A! COSMIC!
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 E643delE! Colon!
Deletion 
inframe! N/A! N/A! COSMIC!
Helical scaffold dimerization domain !
(p. 408 - 654)!
TBK1 L658fs*23! Colon!
Deletion 
frameshift! N/A! N/A! COSMIC!
C-terminal domain!
 (p. 658 - 745)!
TBK1 I397fs*5! Caecum!
Insertion 
frameshift! N/A! N/A! COSMIC!
Near ubiquitin-like domain !
(p. 309 - 384); !
Near helical scaffold dimerization domain !
(p. 408 - 654)!
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Table 2.  Description and location of the point mutations found in the large 
intestine of patient tumor samples (COSMIC and TCGA database) with 
predicted functional impact determined by mutationassessor.org.   
 
To predict the functional impact of the missense TBK1 mutations listed in Table 2, 
each mutation was assessed using the software application at mutationasessor.org.  
Functional impact scores were calculated using the algorithm provided by 
mutationassessor.org, which is based on scores using multiple sequence alignments 
with an assumption that protein function is likely affected by specific substitutions of 
conserved residues.  A “neutral” or “low” score for functional impact predicts that a 
specific mutation would have no influence on the function of the protein of interest 
whereas a “medium” or “high” score predicts that the mutation likely may alter the 
function of the protein102. 
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Figure 29.  APC, KRAS, and PIK3CA mRNA expression correlates with TBK1 
mRNA expression in colorectal adenocarcinomas sampled from TCGA. 
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Figure 29. APC, KRAS, and PIK3CA mRNA expression correlates with TBK1 
mRNA expression in colorectal adenocarcinomas sampled from TCGA. 
Correlation between TBK1 mRNA expression and mRNA expression of APC, TP53, 
KRAS, SYNE1 and PIK3CA in the validated dataset (n=244) of TCGA.  mRNA 
expression data were collected using the RNASeqV2 data are from validated genetic 
profiles of colorectal adenocarcinoma tumor samples in TCGA at 
www.cbioportal.org74.  The Pearson correlation test was used to examine correlation 
between stages of disease.  p-values of <0.05, <0.01, <0.001, <0.0001 correspond 
with (*), (**), (***), and  (***) annotations respectively. 
 
 
 
 
 
 
 
 
 
  
  122 
Figure 30.  IL10 mRNA expression correlates with TBK1 mRNA expression in 
colorectal adenocarcinomas sampled from TCGA. 
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Figure 30.  IL10 mRNA expression correlates with TBK1 mRNA expression in 
colorectal adenocarcinomas sampled from TCGA. Correlation between TBK1 
mRNA expression and IL10 mRNA expression in the validated and provisional 
dataset of TCGA.  mRNA expression data were collected using the RNASeqV2 data 
are from validated (n=244) and provisional (n=382) genetic profiles of colorectal 
adenocarcinoma tumor samples in TCGA at www.cbioportal.org74.  The Pearson 
correlation test was used to examine correlation between stages of disease.  p-
values of <0.05, <0.01, <0.001, <0.0001 correspond with (*), (**), (***), and  (***) 
annotations respectively. 
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Chapter 4: Investigating the role of TBK1 in human colorectal cancer cells 
Introduction 
As discussed in previous chapters, TBK1 is involved in several signaling 
pathways such as pathogen recognition and immune response, inflammatory 
response and oncogenesis40. In particular, several reports have implicated TBK1 as 
a survival factor in cancer cells, especially KRAS-dependent lung cancer cell 
lines45,60,62,66. TBK1 knockdown by RNA interference in these human cancer cell 
lines promotes their apoptosis and suppresses their growth as xenograft tumors in 
immunocompromised mice45,60,66. The TBK1 knockdown has also been shown to 
sensitize tamoxifen-resistant breast cancer cells to tamoxifen treatment72. Despite 
these findings, the role of TBK1 in cancer regulation remained unclear and 
controversial prior to the commencement of this dissertation project. A recent study 
suggested that TBK1 knockdown by the majority of the TBK1 shRNAs has no 
specific effect on the survival of either KRAS-dependent or KRAS-independent 
human cancer cells, suggesting a potential off-target effect of the shRNAs used in 
previous studies73. Furthermore, pharmacological inhibition of TBK1 fails to 
significantly reduce the rate of cancer cell growth, despite the efficient blockade of 
the canonical TBK1 function in IRF3 phosphorylation73.  These findings cause some 
confusion in the field that obviously warrants additional studies.  
As described in Chapter 3 of this dissertation, our study using Tbk1IEC-KO mice 
in conjunction with the Apcmin/+ animal model of colon cancer has revealed an 
inhibitory role for TBK1 in regulating adenoma development. However, the role of 
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TBK1 in regulating the late-stages of CRC remains to be examined. We addressed 
this question by knocking down TBK1 in CRC cells and performing tumor formation 
studies using a xenograft model. In addition, we also employed a small molecule 
inhibitor of TBK1, MRT67307. While we have presented in this dissertation the 
limitations of these models, we found that TBK1 is dispensable for the survival of 
KRAS-competent human colon cancer xenograph tumors. We speculate that this 
may be attributable to the absence of T lymphocytes in this model. 
Results 
To knock down TBK1 in human CRC cells, we transduced human CRC HT-29 
cells with either a control shRNA targeting luciferase or two different TBK1 shRNAs, 
TBK1 shRNA D5 and D9.  The HT-29 cell line is a frequently used CRC cell line that 
carries APC mutations104,105 but is KRAS wildtype. These cells resemble our animal 
studies using the Apcmin/+ mice in Chapter 3 in that they have deregulated Wnt 
signaling due to impaired APC function. Since TBK1 shRNA D5 had a much higher 
knockdown efficiency than TBK1 shRNA D9 (Figure 22A), we used the D5-
transduced HT-29 cells for the xenograft model of studies. To avoid rejection of the 
human cells by mouse immune system, we used the lymphocyte-deficient nude 
(nu/nu) mice as recipients for human colon cancer cell xenograft transplantation106. 
We injected the control or TBK1 shRNA D5 knockdown HT-29 cells into nu/nu mice 
subcutaneously at two sites per mouse, measured the tumor size twice each week, 
and calculated tumor volume based on the formula volume = (length x width2) x 0.52.  
We observed that TBK1 knockdown in HT-29 cells had no effect on size of tumors 
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developing in the immunodeficient xenograft mouse model (Figure 22B, C and D).  
Thus, TBK1 is dispensable for the growth and survival of CRC HT-29 cells under 
xenograft conditions.  
Since TBK1 has been implicated in the survival regulation of KRAS-
dependent cancer cells60,62,66,73, we next performed TBK1 knockdown in a CRC cell 
line, LoVo, a known to carrier of KRAS mutations. We used the more efficient TBK1 
shRNA D5 to knockdown TBK1 in LoVo cells and analyzed cell growth and cell 
death in culture.  After TBK1 knockdown in vitro (Figure 23A), LoVo cells had 
decreased cell numbers and cell viability over time compared to control cells 
transduced with the luciferase shRNA-encoding vector (Figure 23B, C and D). This 
result is consistent with the claim in the literature that TBK1 mediates the survival of 
KRAS-dependent cancer cells60,62,66,73.  
To elucidate the molecular mechanism by which TBK1 mediates LoVo cell 
growth and survival, we examined the effect of TBK1 knockdown on the activation of 
two major kinases, AKT and mTORC1, associated with cell growth and survival. We 
measured the activation of AKT based on its phosphorylation at serine-473 and the 
activation of mTORC1 based on phosphorylation of a downstream protein, S6. We 
used the HT-29 cell line as a control, since the growth and survival of these cells are 
insensitive to TBK1 knockdown. Interestingly, the TBK1 knockdown by shRNA D5 
resulted in inhibition of AKT activation in both the HT-29 and LoVo cells, although 
the effect on S6 phosphorylation was somewhat variable (Figure 24). This finding 
was intriguing, since TBK1 knockdown had no obvious effect on the growth of HT-29 
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in the xenograft model. It is possible that the reduction in AKT phosphorylation may 
be compensated by some other signaling pathways, particularly those downstream 
of the KRAS. It is also important to note that this result is based on only one TBK1 
shRNA, since the shRNA D9 was inefficient in TBK1 knockdown.  
The pharmacological compound MRT67307 is a TBK1 inhibitor that has been 
shown to inhibit the induction of IRF3 phosphorylation and IFN-β production in 
macrophages107. Since the process of shRNA knockdown is long, the system may 
have the potential problem of selecting abnormal cell populations with a growth 
advantage. So, we performed independent studies by employing the TBK1 inhibitor 
MRT67307. Surprisingly, MRT67307 treatment did not appreciably affect the 
phosphorylation of AKT as revealed using the TBK1 knockdown system with HT-29 
and LoVo cells (Figure 25). Moreover, this treatment led to the drastic induction of 
S6 phosphorylation, indicative of mTORC1 activation. The reasons for these 
contradictory results are unclear, but may be due to transient nature of 
pharmacological inhibition as compared to the stability of the knockdown system. 
Discussion 
The results of this study suggest that TBK1 is dispensable for the growth and 
survival of CRC HT-29 cells under xenograft conditions. Taken together with our 
animal studies using Apcmin/+ mice described in Chapter 3, these findings suggest 
that TBK1 may not be involved in the intestinal tumor growth and/or survival of the 
CRC cells under KRAS-competent conditions.  Furthermore, our animal studies 
under lymphocyte-free conditions in Chapter 3 revealed that the tumor-regulating 
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function of TBK1 is dependent upon the presence of functional lymphocytes.  
Therefore, it is possible that the function of TBK1 in CRC cell xenograph tumor 
growth may be masked by the absence of functional T lymphocytes. 
The results of this study suggest a role for TBK1 in regulating the survival of a 
KRAS-dependent CRC cell line, LoVo, although not a KRAS-independent cell line, 
HT-29. This finding KRAS-dependent function of TBK1 is consistent with the 
previous work performed using lung cancer cell lines though the underlying signaling 
mechanism of this function is still unclear. Our attempt to elucidate this molecular 
mechanism revealed some inconsistent results. While TBK1 knockdown using 
shRNA suggests a role for TBK1 in mediating activation of AKT, inhibition of TBK1 
with a pharmacologic inhibitor surprisingly did not lead to AKT inhibition. Instead, the 
TBK1 inhibitor strongly promoted the phosphorylation of S6, a downstream target of 
the metabolic kinase mTORC1.  The reasons for conflicting results are unclear.  As 
discussed above, one difference between the pharmacological inhibition and the 
shRNA knockdown strategies is that the former is a more transient event, whereas 
the latter represents a more steady state following a long period of cell selections. 
Another possibility is that MRT67307 may non-specifically inhibit additional kinases, 
thus causing the activation of the mTORC1 pathway.  Alternatively, these results 
may reflect the loss of the adaptor function of TBK1 in knockdown systems 
compared to the blockade of the kinase function of TBK1 using TBK1 
pharmacological inhibitor. This is possible given that other domains such as the 
ULD, SDD, and CTD of TBK1 mediate the recruitment of TBK1 to specific binding 
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partners and the substrate specificity and phosphorylation by TBK141-43,45,84. Clearly, 
these studies further highlight the high levels of variations in in vitro studies using 
cancer cell lines, emphasizing the necessity of additional studies using different 
approaches including genetic animal models as presented in Chapter 3 and the 
recently developed CRISPR-knockout system.  
  
 
 
 
.  
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Figure 31. TBK1 knock-down in human colon cancer cell line HT-29 has no 
effect on tumor size in a mouse xenograft model. 
 
 
 
 
 
  
HT-29 Control! HT-29 TBK1 D5!
0"
200"
400"
600"
800"
1000"
1200"
1400"
1600"
3" 7" 13" 17" 21"
Tu
m
or
 S
ize
 (m
m
3)
!
Days!
HT-29 Control 
shRNA!
HT-29 TBK1 d5 
shRNA!
22!
23!
24!
25!
26!
27!
28!
7! 13! 17! 21!
W
ei
gh
t (
g)
!
Days!
HT-29 control!
HT-29 TBK1 D5!
HT-29  human colon cancer cell line!
TBK1!
Control          D5               D9!
HSP60!
A B!
C! D!
shRNA:!
HT-29 Control!
!
HT-29 TBK1 D5!
!
HT-29 Control!
HT-29 TBK1 D5!
  132 
Figure 31. TBK1 is dispensable for xenograph tumor growth using KRAS-
competent human HT-29. A) Western blot analysis of TBK1 in HT-29 cells 
transduced with a vector encoding a TBK1 shRNA (D5 or D9) or a control luciferase 
shRNA (control shRNA).  B) Growth curve of xenograph tumors grown in nu/nu mice 
(n=5 each group; two tumors per mouse) injected subcutaneously with HT-29 cells 
transduced with control luciferase shRNA- or TBK1 D5 shRNA-encoding vectors. 
Data are presented as mean ± SD and are a representative of two independent 
experiments. C) Representative image of tumor sizes at day 21 post-injection of 
nu/nu mice with HT-29 cells transduced with control shRNA- or TBK1 D5 shRNA-
encoding vectors. D) Change in weight (g) of the nu/nu mice post-injection with HT-
29 cells transduced with control shRNA- or TBK1 D5 shRNA-encoding vectors. Data 
are presented as mean ± SD. 
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Figure 32. TBK1 knockdown in LoVo cells reduces cell viability in vitro. 
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Figure 32. TBK1 knockdown in LoVo cells reduces cell viability in vitro. A) 
Western blot analysis of TBK1 in LoVo cells transduced with a vector encoding a 
TBK1 shRNA (D5) or a control luciferase shRNA (control shRNA). LoVo cells 
transduced with control luciferase shRNA- or TBK1 D5 shRNA-encoding vectors 
were seeded at B) 50 × 103 cells/well or C) 500 × 103 cells/well.  Live (top B and C) 
and dead (middle B and C) cells were counted at indicated days post-seeding using 
trypan blue exclusion. Cell survival was determined as the percentage of dead cells 
(bottom B and C) in total cells counted. D) Representative images of LoVo cells 
transduced with a vector encoding a TBK1 shRNA (D5) or a control luciferase 
shRNA (control shRNA) in culture at days 1 and 4 post-seeding. Data represents 
one experiment. 
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Figure 33. TBK1 knockdown in CRC cells inhibits AKT and mTORC1 
activation.  
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Figure 33. TBK1 knockdown in CRC cells inhibits AKT and mTORC1 
activation. Western blot analysis of the indicated proteins in whole-cell lysates from 
HT-29 and LoVo cells stably transduced with control luciferase shRNA- or TBK1 
shRNA-encoding vectors as indicated.  Data represents three independent 
experiments. 
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Figure 34.  Pharmacological inhibition of TBK1 activates AKT and mTOR 
pathways in CRC cells. 
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Figure 34.  Figure 25.  Pharmacological inhibition of TBK1 activates AKT and 
mTOR pathways in CRC cells.  Western blot analysis of the indicated proteins in 
whole-cell lysates from HT-29 and LoVo cells with MRT67307 (TBK1 inh) or dimethyl 
sulfoxide (DMSO) at indicated times (hours).  Data represents two independent 
experiments. 
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Chapter 5: Overview, Discussion and Future Directions 
The primary objective of this work was to determine the role of TBK1 in the 
tumorigenic process in vivo. We present the first in vivo model to demonstrate 
TBK1’s function during intestinal adenoma development and suggest a mechanism 
of TBK1 action. Moreover, this project presents the use of a novel approach in 
determining TBK1’s role in early cancer development in vivo in addition to the 
xenograft model currently described in the literature for other cancer types.  The 
following sections will summarize and discuss the major findings of this dissertation.  
1. TBK1 is a novel inhibitor of intestinal adenoma growth 
In Chapter 3, we generated and characterized an innovative mouse model in 
which TBK1 is conditionally deleted in IECs, leading to the discovery that TBK1 has 
a tumor-suppressive function in the intestine. In particular, IEC-specific Tbk1 ablation 
promotes adenoma development in mice carrying a heterozygous mutation in the 
tumor suppressor Apc gene, an alteration commonly found in the earlier stages of 
CRC development16.18  The effect of TBK1 deficiency on adenoma formation is 
diminished in the absence of lymphocytes demonstrated herein by IEC-specific Tbk1 
deletion in Apcmin/+ mice having no effect on the formation of intestinal polyps under 
lymphocyte-free conditions. Those results suggest that IEC-specific TBK1 regulates 
an aspect of adaptive immune homeostasis.    
Moreover, intestinal T lymphocytes, specifically Tregs, are required for 
immune homeostatic maintenance of the gut, suppressing inflammatory responses 
to commensal organisms in an IL-10-dependent manner. 33, 32 While IEC-specific 
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TBK1 does not seem to regulate IL-10 expression in intestinal Tregs in Apcmin/+ mice, 
it is required for IL-10 expression by IELs, another major producer of intestinal IL-
1033, 32, during the early stages of the tumorigenic process. Indeed, intestinal IELs 
suppression of intestinal inflammation is IL-10-mediated.39 Thus, we identified a new 
role for TBK1 as an important facilitator of crosstalk between IECs and intestinal 
IELs that controls the expression of Il10 under an Apcmin/+ background. It is important 
to confirm impaired IL-10 protein levels in intestinal IELs upon IEC-specific Tbk1 
deletion in Apcmin/+ mice to corroborate our findings. In later experiments, we will 
perform IL-10-specific intracellular staining and use flow cytometry to determine IL-
10 protein expression in IELs at the single-cell level and we expect impaired IL-10 
production by IELs after IEC-specific Tbk1 ablation. 
Given that impaired IL-10 production in the intestine is linked to enhanced 
inflammatory disease and intestinal tumorigenesis37,108-111, it is likely that the 
diminished Il10 expression by the IELs contributes to the elevated adenoma 
formation in the Apcmin/+Tbk1IEC-KO mice.  To confirm this, we are generating 
Apcmin/+Tbk1IEC-KO mice on an IL-10-deficient background.  We expect the difference 
between Apcmin/+ and Apcmin/+Tbk1IEC-KO mice to be abolished after Il10 deletion.  
The next question to be addressed is how TBK1 functions within IECs to 
affect Il10 expression by IELs.  We hypothesize that TBK1 may regulate the 
expression of either surface protein(s) or secretory factor(s) by IECs that in turn 
induces IL-10 production by IELs.  Considering that the role of TBK1 is well 
established in regulating type I interferon induction and that IL-10 is an interferon-
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responsive gene95,112-116, it is possible that TBK1 regulates the expression of type I 
interferons by IECs thereby regulating IL-10 expression by IELs.  While the 
expression levels of IFN-α and -β were comparable in the intestines of Apcmin/+ and 
Apcmin/+ Tbk1IEC-KO mice, it is possible that potential differences in their expression 
could be masked by lack of commensal stimulation of IECs during intestinal 
preparation prior to analysis.  To overcome this technical obstacle, we will stimulate 
IECs with PRR agonists after intestinal preparation prior to analysis of type I 
interferon expression. We expect defective type I interferon expression upon PRR 
stimulation in IECs deficient in TBK1.   
If TBK1 is dispensable for IFN expression by IECs, an alternative hypothesis 
may be that TBK1 regulates the expression of transmembrane protein semaphorin 
(Sema) 7A, thus regulating IL-10 expression by IELs.  Semaphorins are classically 
described as regulators of neuronal cell signaling but have recently been found to 
function in various organs and cell types, including immune cells114.  Specifically, 
Sema7A is expressed in brain, lung, intestines, thymus, lymphocytes, and 
macrophages117 to name a few.  It is also expressed on thymocytes preferentially 
during selection and during activation in the periphery46,57,116.  Sema7a deficiency in 
T cells leads to a reduction in inflammatory responses, whereas its overexpression 
can stimulate macrophages and monocytes via interaction with α1β1 integrin to 
secrete proinflammatory cytokines 118,119.  A recent study examined Sema7a in the 
intestine and found that its expression on IECs induces IL-10 production by intestinal 
macrophages to negatively regulate chemically-induced colitis120.  We will examine 
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the expression level of Sema7a in IECs of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. In 
addition, we will employ a more systematic approach to compare gene expression 
profiles between the IECs of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice by RNA 
sequencing. Together, these future studies will likely provide more insight into the 
mechanism underlying the IEC-specific function of TBK1 in regulating adenoma 
formation. 
2.  TBK1 is dispensable for growth and survival of KRAS-independent human CRC 
cells  
In Chapter 4, we employed a TBK1 knockdown system using KRAS-
dependent and KRAS-independent human CRC cell lines, leading to the conclusion 
that, under T lymphocyte-free conditions, TBK1 is dispensable for the growth and 
survival of xenograph tumors derived from KRAS-independent human CRC cell 
lines. However, consistent with earlier findings, TBK1 regulates the survival of a 
KRAS-dependent CRC cell lines in vitro.  Given the immunocompromised status of 
the CRC cell recipient mice, it would be interesting to determine whether the tumor-
regulating function of TBK1 in KRAS-independent human CRC cells is masked by 
the absence of T lymphocytes similar to what we observed in our study using 
Tbk1IEC-KO mice in Apcmin/+ background. Furthermore, our attempt to elucidate the 
molecular mechanism underlying this function of TBK1 was met with inconsistent 
results further highlighting the need for multiple approaches to gain more insight.  
As mentioned in Chapter 2, the use of animal models has revealed important 
cellular and molecular players involved in CRC development and progression.  One 
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challenge in determining the in vivo function of TBK1 has been the embryonic 
lethality of conventional Tbk1 KO mice56. In this project, we overcame this obstacle 
by generating Tbk1 IEC-conditional KO mice, which provided genetic evidence that 
TBK1 suppresses intestinal adenoma development by regulating the intestinal 
adaptive immune system. It would be interesting to determine if the cell survival 
function of TBK1 would persist in the presence of T lymphocytes since these studies 
used immunocompromised hosts lacking T lymphocytes. Ironically, we show in 
Chapter 4 that TBK1 deficiency in KRAS-independent human CRC cells had no 
effect on xenograph tumor growth in immunocompromised hosts, a finding that 
parallels our results in Chapter 3 where the IEC specific-TBK1 deficiency has little 
effect on intestinal polyp formation in Apcmin/+ mice lacking lymphocytes. Further 
studies are needed to determine if TBK1 regulates a part of the adaptive immune 
homeostasis that is masked by the absence of T cells in xenograph tumor models.  
Furthermore, we have shown here that TBK1 inhibits intestinal adenoma 
development at early stages under an Apcmin/+ background.  Because the survival 
function of TBK1 has been mainly attributed to the human cancer cells dependent 
upon KRAS, the question remains if TBK1 exerts similar or distinct functions in 
different oncogenic pathways under lymphocyte-competent conditions.  The findings 
of this project begin to address this question, which could have significant clinical 
implications and impact the direction of the field.  There is a strong and very 
significant positive correlation between TBK1 expression and the expression of APC 
in the patient samples of colorectal adenocarcinomas, a finding that is consistent 
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with the results using our Apcmin/+ mice with IEC-specific Tbk1 ablation presented 
herein. A similar trend – a strong and very significant positive correlation – was also 
observed between expression of TBK1 and KRAS in patient samples.  One could 
hypothesize that TBK1 negatively regulates tumor progression in KRAS mutant 
colon cancer given the strong relationship between expression of the two genes.  In 
support of this hypothesis, levels of TBK1 expression correlate positively between 
early and late stages of disease.  Thus one could speculate that TBK1 functions 
similar in the late stages of colorectal cancer which have acquired KRAS and 
PIK3CA genetic mutations as it does during early stages of disease where LOH of 
APC commonly occurs.  Additional analyses testing this idea using KRAS and 
PIK3CA in vivo models as presented in this dissertation using Apcmin/+ mice would 
provide a better understanding of the molecular mechanisms mediating 
advancement of the disease.   
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Chapter 6 Materials and Methods 
Mice. Age-matched Tbk1 intestinal epithelial cell-conditional KO (Tbk1IEC-KO) and 
wildtype mice were generated by crossing Tbk1 floxed mice 48(Taconic) with villin-
Cre mice (Jackson Laboratory). IEC-conditional Tbk1 mice were further crossed with 
Apcmin/+ mice (Jackson Laboratory) to generate Apcmin/+ or Apcmin/+Tbk1IEC-KO mice. In 
some experiments, the Apcmin/+Tbk1IEC-KO mice were further crossed with Rag1-/- 
(Rag1 KO) (Jackson Laboratory) mice to generate Apcmin/+ Rag1 KO or 
Apcmin/+Tbk1IEC-KO Rag1 KO mice. The Tbk1 floxed mice had a 129Sv/Ev 
background, villlin Cre transgenic mice had a mixed background, the Apcmin/+ and 
Rag1 KO mice were of C57BL/6 background. The mice were maintained at The 
University of Texas M.D. Anderson Cancer Center facility under specific pathogen-
free conditions. Animal experiments were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee. 
 
Antibodies and reagents.  Antibodies for recognizing TBK1, phospho-AKT ser473 
(D9E), AKT1 (B-1), phospho-S6 Ser235/236 (D57.2.2E), and S6 (54D2) were from 
Cell Signaling. β actin (C-4), HSP 60 and HSP 70 were from Sigma Aldrich.  The 
MRT673037 TBK1 inhibitor was from Chemexpress. 
 
Cell lines.  The human colon cancer cell lines HT-29 and LoVo and the human 
embryonic kidney (HEK) 293 cells were cultured in DMEM (Dulbecco’s modified 
Eagle’s medium) supplemented with 10% FBS and 1% streptomycin/penicillin. 
  147 
 
Gene silencing.  To produce the lentiviral particles, the pLKO.1 vectors encoding 
control luciferase or encoding specific TBK1 shRNA (either TBK1 shRNA D5 or D9) 
were transfected into HEK293 cells (using the calcium method) along with the 
packaging vectors psPAX2 and pMD2 provided by X. Qin. Human colon cancer cell 
lines were then infected with packaged viruses carrying either luciferase, TBK1 
shRNA D5 or TBK1 shRNA D9.  After 48 hours, infected cells were treated with 
puromycin (1 ug/mL) for seven days to select for vector positive cells. 
 
IEC isolation.  Intestines were harvested, cut longitudinally and wash with PBS to 
remove fecal contents. Intestines were incubated in HBSS (Hank's Buffered Salt 
Solution) containing 10 mM EDTA at 37°C for five minutes in water bath.  
Supernatants were discarded and intestines incubated with PBS containing 1 mM 
EDTA and 1 mM DTT for 15 minutes in 37°C water bath.  Suspension was shook 
vigorously and supernatants were collected and washed twice with ice-cold PBS.  
 
IEL and LP cell isolation. Mice were sacrificed and intestine resected. Feces were 
removed by flushing with cold HBSS. The intestines were longitudinally opened, cut 
into ~0.5cm pieces and incubated in Solution I (5% FBS, 2 mM EDTA, 1mM DTT, 10 
mM HEPES in HBSS) at 37°C for twenty minutes. Pieces were vortexed briefly and 
pass intestine through a (100 micron) filter. Supernatant were collected as IELs and 
IECs. New Solution I was added to the intestinal pieces and subsequent steps 
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repeated to collect more IELs.  Intestinal pieces were then rinsed with HBSS with 
10mM HEPES and supernatant combined with IEL and IEC collected.  Percoll 
density gradient or CD45 bead separation was used to enrich for IELs. Intestinal 
pieces were incubated in Solution II (5% FBS, 1 mg/mL Collagenase D, 0.1 mg/mL 
Dnase I in RPMI 1640) at 37°C for 30 minutes.  Suspension was vortexed briefly and 
filtered to collect the lamina propria cells.  New solution II was added to the intestinal 
pieces and subsequent steps repeated.  Flow-through was combined and 
suspension was centrifuged at 300g for ten minutes.  Supernatant was discarded 
and LP cells were stained with antibody or used in indicated experiments.  
 
Bromodeoxyuridine (BrdU) assay.  BrdU incorporation assay was performed 
according to manufacturer’s (Life Technologies) instructions. Six to eight week old 
mice were injected with BrdU (Sigma-Aldrich) intraperitoneally at 50 ug per gram of 
mouse body weight.  Five hours after injection, mice were sacrificed and intestines 
were resected and fixed in 10% Buffered Formalin Phosphate (Fisher Scientific) 
overnight.  Intestines were cleaned of feces, swiss-rolled, and paraffin-embedded. 
Five micron BrdU-labeled tissue sections were deparafinized using xylene, hydrated 
in series of graded ethanol as preparation for BrdU immunohistochemical staining.  
Per the manufacturer’s kit, tissue sections were peroxidase quenched, trypsinized, 
denatured, blocked and incubated with biotinylated anti-BrdU antibodies.  After 
washing with PBS, tissue was incubated with streptavidin-peroxidase, rinsed, 
developed, and counterstained.   After tissue dehydration, tissue was mounted using 
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Permount (Fisher Scientific).  Tissues were analyzed using brightfield filters of 
Olympus BX41 microscope with Olympus DP70 camera.  BrdU positive cells were 
counted using count tool of Adobe Photoshop CS4 software and counting the 
number of positively labeled cells and hematoxylin stained nuclei of either crypt, 
villus, or microadenoma within the image from which percentage positive was 
determined per crypt, per villus, or per microadenoma.   
 
TUNEL assay. For TUNEL staining, the DeadEnd Fluorometric TUNEL System 
(Promega) was employed.  Per the manufacturer’s instructions, formalin fixed five 
micron paraffin-embedded tissue sections were deparafinized and dehydrated using 
xylene and graded ethanol washes.  Sections were immersed in 0.85% NaCl 
followed by PBS washing and 10% buffered formalin fixation.  After PBS washing, 
sections were digested using Proteinase K solution at 20 ug/mL for 20 minutes at 
room temperature.  Sections were PBS washed and refixed in 10% buffered formalin 
and rewashed in PBS.  Sections were biotin blocked using Avidin/Biotin Blocking Kit 
from Vector Laboratories, Inc. After washing in PBS, sections were equilibrated 
using manufacturer-provided equilibration buffer in the TUNEL System kit. 
Fragmented DNA within cells were fluorescein-labeled for one hour at 37°C by using 
rTdT reaction mix provided by the TUNEL System kit.  The reaction was terminated 
and washed in PBS.  Prolong gold anti-fade reagent plus DAPI (Life Technologies) 
was used for tissue mount. Tissues were analyzed using fluorescent filters on 
Olympus BX41 microscope with an Olympus DP70 camera.  TUNEL positive cells 
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were blindly counted using count tool of Adobe Photoshop CS4 software and 
counting the number of positively labeled cells and DAPI stained nuclei of the villus 
within the image from which percentage positive was determined per villus.  For the 
microadenomas, TUNEL positive cells were counted using count tool of Adobe 
Photoshop CS4 software while DAPI stained nuclei were counted using Cell Profiler 
version 3 cell image analysis software (http://www.cellprofiler.org).  The analysis 
pipeline included identifying region of microadenoma and cropping within individual 
image, saving cropped images for subsequent identification and automated 
enumeration of DAPI stained nuclei as determined by automated image 
thresholding.  
 
Xenograft injection.  Transduced HT29 cells with TBK1 shRNA (TBK1 KD) (2 × 106  
cells) or control luciferase shRNA (2 × 106 cells) that were injected into 
immunodeficient nu/nu mice (n=5 each group; two injected tumors per mouse) 
subcutaneously.  Tumor size was measured twice per week and tumor volume was 
calculated using the defined formula (tumor volume = (length x width2) x 0.52). 
Weight of the mice was measured twice per week post injection.   
 
Ki67 immunohistochemical staining.  Mice were sacrificed and intestines were 
resected and fixed in 10% Buffered Formalin Phosphate (Fisher Scientific) overnight.  
Intestines were cleaned of feces, swiss-rolled, and paraffin-embedded. Tissue 
sections were deparafinized using xylene, hydrated in series of graded ethanol as 
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preparation for immunohistochemical staining.  Antigen was retrieved by boiling 
tissue section in Citrate Buffer pH 6 (Sigma-Aldrich) for 20 minutes.  Tissue was 
allowed to cool to room temperature, was blocked using 3% BSA in PBS, and 
incubated overnight with Ki67 (D3B5) antibody (Cell Signaling).  After one hour 
incubation with secondary antibody, tissue was developed using DAB substrate kit 
(Abcam).  Tissues were blindly using bright field filters of Olympus BX41 microscope 
with Olympus DP70 camera and counted blindly using Adobe Photoshop CS6 count 
tool.   
 
Western blot.  Whole-cell extracts of the cells were harvested using cell extraction 
buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% 
deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 50 mM p-nitrophenyl phosphate 
and 0.3 μM Aprotinin. Samples were extracted for ten minutes on ice and 
centrifuged at 13,000 RPM for one minute at 4°C. Lysates were analyzed for protein 
quantity using Bradford assay. Proteins were separated using SDS-PAGE and 
proteins were transferred to nitrocellulose membrane. Membranes were blocked 
using 5% non-fat dry milk at room temperature for one hour. Membranes were 
incubated with primary antibody indicated overnight at 4°C. Detection was performed 
using enhanced chemiluminescence reagents and exposed to light film. 
 
Flow cytometry. Single-cell suspensions of IELs and lamina propria immune cells 
were subjected to flow cytometry using LSR II (BD Bioscience) flow cytometer.  
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FlowJo software was used to analyze the data.  The fluorescence-labeled antibodies 
that were used included TCR γδ FITC-conjugated (BD bioscience), (eBioscience); 
CD11c Pacific Blue-conjugated (BD Bioscience); CD45 PE-conjugated (BD 
Bioscience); CD11b APC-Cy7-conjugated (BD Bioscience); and TCRβ APC-
conjugated (eBioscience). 
 
Real-time quantitative RT-PCR (qPCR). For RNA extraction of tissues, intestines 
were resected cleaned of feces using ice cold PBS.  Tissues were flash frozen in 
liquid nitrogen and ground using a pestle and mortar. Total RNA was isolated using 
TRIzol reagent (Invitrogen) and subjected to cDNA synthesis using RNase H-reverse 
transcriptase (Invitrogen) and oligo (dT) primers. For cells, TRIzol reagent was 
added directly.  Real-time quantitative PCR was performed in triplicates, using 
iCycler Sequence Detection System (Bio-Rad) and iQTM SYBR Green Supermix 
(Bio-Rad). The expression of individual genes was calculated by a standard curve 
method and normalized to the expression of beta-actin.  The gene-specific primer 
sets used (all for mouse genes) were as follows in the table below. 
Gene Primer Primer sequence   
mIl10 forward  CCAGAGCCACATGCTCCTAGA 
 reverse GGTCCTTTGTTTGAAAGAAAGTCTTC 
mTnfα forward  CATCTTCTCAAAATTCGAGTGACAA 
 reverse CCAGCTGCTCCTCCACTTG 
mIl6 forward  CACAGAGGATACCACTCCCAACA 
  153 
 reverse TCCACGATTTCCCAGAGAACA 
mIl17a forward  AGCGATGGTGGATGGCTCATGGTTAG 
 reverse AGCTTTCCCTCCGCATTGACACAG 
mCxcl9 forward  TAGGCAGGTTTGATCTCCGT 
 reverse CGATCCACTACAAATCCCTCA 
mCxcl10 forward  CCTATGGCCCTCATTCTCAC 
 reverse CTCATCCTGCTGGGTCTGAG 
mCxcl11 forward  CGCCCCTGTTTGAACATAAG 
 reverse CTGCTGAGATGAACAGGAAGG 
mCcl2 forward  GGGATCATCTTGCTGGTGAA 
 reverse AGGTCCCTGTCATGCTTCTG 
mIfnb forward  AGCTCCAAGAAAGGACGAACAT 
 reverse GCCCTGTAGGTGAGGTTGATCT 
mIfna forward  AGTCCATCAGCAGCTCAATGAC 
 reverse AAGTATTTCCTCACAGCCAGCAG 
mIfng forward  CAGCAACAGCAAGGCGAAA 
 reverse CTGGACCTGTGGGTTGTTGAC 
mIl17f forward  CCCATGGGATTACAACATCACTC 
 reverse CACTGGGCCTCAGCGATC 
mLgr5 forward  TCCAACCTCAGCGTCTTC 
 reverse TGGGAATGTGTGTCAAAG 
mAxin2 forward  TCCATACAGGAGGATGCTGAAG 
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Mouse Reg3b qPCR primers set (Primer Pair ID M_Reg3b_1- gene ID 18489) was 
purchased from Sigma-Aldrich.  
 
AOM and DSS experiments.  For the chemical-induced colitis model, mice were 
treated with dextran sodium sulfate (DDS)121 (MP Biomedical LLC) as indicated for 
either five or seven days with two-day water recovery period70. Mice were weighed 
once per day during this treatment period and sacrificed at day two after water 
recovery.  The small intestine and colons were resected, formalin-fixed, sectioned, H 
& E stained, and histologically scored based on the criteria in Table 1.  For the 
carcinogen-induced, chronic inflammation-induced colon cancer model, mice were 
treated with a single dose of azoxymethane (AOM) (Sigma-Aldrich) and three cycles 
of 2.5% DSS for five days and water for 14 days92.  Mice were weighed once per 
 reverse TTCGTCACTCGCCTTCTTGA 
mMuc2 forward  ATGCCCACCTCCTCAAAGAC 
 reverse GTAGTTTCCGTTGGAACAGTGAA 
mBclXL forward  TCTGAATGACCACCTAGAGC 
 reverse GGTCAGTGTCTG GTCACTTC 
mIl22 forward  TCCGAGGAGTCAGTGCTAAA 
 reverse AGAACGTCTTCCAGGGTGAA 
mIl1β forward  AAGCCTCGTGCTGTCGGACC 
 reverse TGAGGCCCAAGGCCACAGGT 
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week throughout treatment.  After sacrificing the mice, the colons were resected, 
measured in length, and formalin-fixed overnight.  Intestines were cleaned of feces 
and polyps were counted using Olympus SZX10 stereomicroscope. 
 
Adenoma and microadenoma analysis. For intestinal adenoma analyses, mice 
were sacrificed and intestines were resected and formalin-fixed overnight. Intestinal 
feces were cleaned out and tissues were cut longitudinally.  Using Olympus SZX10 
stereomicroscope, Olympus DP70 camera, and Olympus CellSens Standard 
software, adenomas were counted and measured for length after staining with 0.2 % 
methylene blue and decolorizing with ethanol.   For microadenoma analyses, mice 
were sacrificed and intestines were resected and formalin-fixed overnight. Intestinal 
feces were cleaned out and tissues were cut longitudinally and swiss-rolled. 
Intestines were cleaned of feces, cut longitudinally, swiss-rolled, and paraffin-
embedded. H&E stained section at 100 micron intervals through 500 microns of the 
intestinal tissue was scored for microadenomas defined as histological dysplastic 
lesions characterized by focal areas of abnormally large gland(s)17. 
 
Statistical analysis.  GraphPrism 6 (GraphPad, La Jolla, CA, USA) was used where 
indicated for two-tailed unpaired t-tests. p-values <0.05 and <0.01 correspond with 
(*) and (**) respectively.  For TCGA dataset analyses, RNA expression were 
analyzed using the RNASeqV2 data from validated and/or provisional genomic and 
transcriptomic profiles of colorectal adenocarcinoma tumor samples and were 
accessed on December 12, 2015 at www.cbioportal.org74. Copy-number and overall 
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survival data were accessed similarly. GraphPrism 6 was used for statistical 
analyses and graphing. The Pearson correlation test was used to examine 
correlation between mRNA expressions and log2 copy-number of a gene in the 
TCGA datasets where correlations indicated.  The survival data were visualized as 
correlation between mRNA expression or log2 copy-number of a gene and overall 
survival and analyzed using the Pearson correlation test. One-way ANOVA with 
Tukey’s multiple comparisons test was used to analyze mean differences in mRNA 
expression levels between groups of putative copy-number alternations with the 
exception of the putative amplification group (n=1) and visualized as mean ± 95% 
confidence intervals with alpha of 0.05. The threshold for statistical significance in all 
test was p<0.05 with two-sided analysis.  p-values of <0.05, <0.01, <0.001, <0.0001 
correspond with (*), (**), (***), and  (***) annotations respectively. 
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